Subcutaneous Biologics Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Biologic, Type of Therapy, End User, Payment Method Employed, Therapeutic Area, Drug Delivery Device, Geographical Regions, Leading Players and Sales Forecast of Drugs

Table of Contents

1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases

3. MARKET DYNAMICS
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Key Market Segmentation
3.7. Robust Quality Control
3.8. Limitations

4. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Future Estimates
4.2.2. Currency Coverage and Foreign Exchange Rate
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations and Foreign Exchange Rates
4.2.2.3. Impact of Foreign Exchange Rate Volatility on the Market
4.2.2.4. Strategies for Mitigating Foreign Exchange Risk
4.2.3. Trade Policies
4.2.3.1. Impact of Trade Barriers on the Market
4.2.3.2. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.4. Recession
4.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
4.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution

5. EXECUTIVE SUMMARY

6. INTRODUCTION
6.1. Chapter Overview
6.2. Types of Therapeutic Molecules
6.3. Biologically Derived Molecules
6.3.1. Type of Products
6.3.2. Routes of Administration and Formulations
6.3.3. Subcutaneous Formulations
6.3.3.1. Approaches in Subcutaneous Delivery of Biologics
6.3.3.1.1. Reformulation
6.3.3.1.2. Differing Potencies
6.3.3.1.3. Novel Technologies
6.3.3.2. Methods of Subcutaneous Administration
6.3.3.3. Advantages of Subcutaneous Administration
6.3.3.4. Limitations of Subcutaneous Administration
6.4. Regulatory Considerations
6.4.1. Medical Devices
6.4.2. Drug Device Combination Products
6.5. Future Perspectives

7. APPROVED SUBCUTANEOUS BIOLOGICS: MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Approved Subcutaneous Biologics: Overall Market Overview
7.2.1. Analysis by Initial Approval Year
7.2.2. Analysis by Type of Biologic
7.2.3. Analysis by Type of Therapy
7.2.4. Analysis by Route of Administration
7.2.5. Analysis by Method of Administration
7.2.6. Analysis by Dosing Frequency
7.2.7. Analysis by Concentration of Dose
7.2.8. Analysis by Target Disease Indication
7.2.9. Analysis by Therapeutic Area
7.2.10. Analysis by Type of Drug Delivery Device
7.3. Approved Subcutaneous Biologics: List of Developers
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters (Region)
7.3.4. Analysis by Location of Headquarters (Country)
7.3.5. Most Active Developers: Analysis by Number of Approved Drugs

8. APPROVED SUBCUTANEOUS BIOLOGICS: SUCCESS PROTOCOL ANALYSIS
8.1. Chapter Overview
8.2. Methodology
8.3. Success Protocol Analysis of Top Approved Subcutaneous Biologics
8.3.1. BENLYSTA® (Human Genome Sciences)
8.3.1.1. Overview
8.3.1.2. Development History
8.3.1.3. Phase of Development, Route of Administration, and Target Disease Indication
8.3.1.4. Success Protocol Analysis
8.3.2. BESREMi® (PharmaEssentia)
8.3.2.1. Overview
8.3.2.2. Development History
8.3.2.3. Phase of Development, Route of Administration, and Target Disease Indication
8.3.2.4. Success Protocol Analysis
8.3.3. COSENTYX® (Novartis)
8.3.3.1. Overview
8.3.3.2. Development History
8.3.3.3. Phase of Development, Route of Administration, and Target Disease Indication
8.3.3.4. Success Protocol Analysis
8.3.4. DARZALEX FASPRO® / DARZALEX® SC (Halozyme)
8.3.4.1. Overview
8.3.4.2. Development History
8.3.4.3. Phase of Development, Route of Administration, and Target Disease Indication
8.3.4.4. Success Protocol Analysis
8.3.5. DUPIXENT® (Regeneron Pharma)
8.3.5.1. Overview
8.3.5.2. Development History
8.3.5.3. Phase of Development, Route of Administration, and Target Disease Indication
8.3.5.4. Success Protocol Analysis
8.3.6. Enbrel® (Amgen)
8.3.6.1. Overview
8.3.6.2. Development History
8.3.6.3. Phase of Development, Route of Administration, and Target Disease Indication
8.3.6.4. Success Protocol Analysis
8.3.7. HEMLIBRA® (Roche)
8.3.7.1. Overview
8.3.7.2. Development History
8.3.7.3. Phase of Development, Route of Administration, and Target Disease Indication
8.3.7.4. Success Protocol Analysis
8.3.8. Prolia® / Pralia® (Amgen)
8.3.8.1. Overview
8.3.8.2. Development History
8.3.8.3. Phase of Development, Route of Administration, and Target Disease Indication
8.3.8.4. Success Protocol Analysis
8.3.9. STELARA® (Janssen Biotech)
8.3.9.1. Overview
8.3.9.2. Development History
8.3.9.3. Phase of Development, Route of Administration, and Target Disease Indication
8.3.9.4. Success Protocol Analysis
8.3.10. Trulicity® (Eli Lilly)
8.3.10.1. Overview
8.3.10.2. Development History
8.3.10.3. Phase of Development, Route of Administration, and Target Disease Indication
8.3.10.4. Success Protocol Analysis
8.4. Conclusion

9. CLINICAL-STAGE SUBCUTANEOUS BIOLOGICS: MARKET LANDSCAPE
9.1. Chapter Overview
9.2. Clinical-stage Subcutaneous Biologics: Overall Market Overview
9.2.1. Analysis by Phase of Development
9.2.2. Analysis by Type of Biologic
9.2.3. Analysis by Type of Therapy
9.2.4. Analysis by Mechanism of Action
9.2.5. Analysis by Dosing Frequency
9.2.6. Analysis by Drug Designation
9.2.7. Analysis by Target Disease Indication
9.2.8. Analysis by Therapeutic Area
9.3. Clinical-stage Subcutaneous Biologics: List of Developers
9.3.1. Analysis by Year of Establishment
9.3.2. Analysis by Company Size
9.3.3. Analysis by Location of Headquarters
9.3.4. Most Active Developers: Analysis by Number of Clinical-stage Drugs

10. SUBCUTANEOUS FORMULATION: TECHNOLOGY LANDSCAPE
10.1. Chapter Overview
10.2. Subcutaneous Formulation: Technology Landscape
10.2.1. Analysis by Fundamental Principle
10.2.2. Analysis by Type of Molecule
10.2.3. Analysis by Route of Administration
10.2.4. Analysis by Therapeutic Area
10.2.5. Analysis by Key Characteristics
10.3. Subcutaneous Formulation: Technology Developers Landscape
10.3.1. Analysis by Year of Establishment
10.3.2. Analysis by Company Size
10.3.3. Analysis by Location of Headquarters

11. TECHNOLOGY COMPETITIVENESS ANALYSIS
11.1. Chapter Overview
11.2. Assumptions and Key Parameters
11.3. Methodology
11.4. Technology Competitiveness Analysis: Subcutaneous Formulation Technology
11.4.1. Subcutaneous Formulation Technology Developed by Companies based in North America (Peer Group I)
11.4.2. Subcutaneous Formulation Technology Developed by Companies based in Europe (Peer Group II)
11.4.3. Subcutaneous Formulation Technology Developed by Companies based in Asia-Pacific (Peer Group III)

12. SUBCUTANEOUS FORMULATION TECHNOLOGY PROVIDERS: COMPANY PROFILES
12.1. Chapter Overview
12.2. Technology Developers Based in North America
12.2.1. CD Bioparticles
12.2.1.1. Company Overview
12.2.1.2. Technology Portfolio
12.2.1.3. Recent Developments and Future Outlook
12.2.2. Creative Biolabs
12.2.2.1. Company Overview
12.2.2.2. Technology Portfolio
12.2.2.3. Recent Developments and Future Outlook
12.2.3. Creative BioMart
12.2.3.1. Company Overview
12.2.3.2. Technology Portfolio
12.2.3.3. Recent Developments and Future Outlook
12.2.4. Pacira BioSciences
12.2.4.1. Company Overview
12.2.4.2. Financial Information
12.2.4.3. Technology Portfolio
12.2.4.4. Recent Developments and Future Outlook
12.2.5. The Wyss Institute
12.2.5.1. Company Overview
12.2.5.2. Technology Portfolio
12.2.5.3. Recent Developments and Future Outlook
12.2.6. Xeris Biopharma
12.2.6.1. Company Overview
12.2.6.2. Financial Information
12.2.6.3. Technology Portfolio
12.2.6.4. Recent Developments and Future Outlook
12.3. Technology Developers Based in Europe
12.3.1. Adocia
12.3.1.1. Company Overview
12.3.1.2. Financial Information
12.3.1.3. Technology Portfolio
12.3.1.4. Recent Developments and Future Outlook
12.3.2. Ascendis Pharma
12.3.2.1. Company Overview
12.3.2.2. Financial Information
12.3.2.3. Technology Portfolio
12.3.2.4. Recent Developments and Future Outlook
12.4. Technology Developers Based in Asia-Pacific
12.4.1. Alteogen
12.4.1.1. Company Overview
12.4.1.2. Technology Portfolio
12.4.1.3. Recent Developments and Future Outlook
12.4.2. Foresee Pharmaceuticals
12.4.2.1. Company Overview
12.4.2.2. Financial Information
12.4.2.3. Technology Portfolio
12.4.2.4. Recent Developments and Future Outlook

13. SUBCUTANEOUS FORMULATION TECHNOLOGIES: PARTNERSHIPS AND COLLABORATIONS
13.1. Chapter Overview
13.2. Partnership Models
13.3. Partnerships and Collaborations: Subcutaneous Formulation Technology
13.3.1. Analysis by Year of Partnership
13.3.2. Analysis by Type of Partnership
13.3.3. Analysis by Year and Type of Partnership
13.3.4. Analysis by Type of Partner
13.3.5. Analysis by Location of Headquarters of Partner
13.3.6. Analysis by Therapeutic Area
13.3.7. Most Active Players: Analysis by Number of Partnerships
13.4. Analysis by Geography
13.4.1. Intracontinental and Intercontinental Agreements
13.4.2. International and Local Agreements

14. SUBCUTANEOUS DRUG DELIVERY SYSTEMS: MARKET LANDSCAPE
14.1. Chapter Overview
14.2. Types of Subcutaneous Drug Delivery Systems
14.2.1. Large Volume Wearable Injectors
14.2.1.1. Large Volume Wearable Injectors for Non-Insulin Drugs: Market Landscape
14.2.1.1.1. Analysis by Status of Development
14.2.1.1.2. Analysis by Type of Device
14.2.1.1.3. Analysis by Usability
14.2.1.1.4. Analysis by Type of Dose
14.2.1.1.5. Analysis by Type of Drug Container
14.2.1.1.6. Analysis by Mode of Drug Filling
14.2.1.1.7. Analysis by Container Volume (mL)
14.2.1.1.8. Analysis by Route of Administration
14.2.1.1.9. Analysis by Mode of Injection
14.2.1.1.10. Analysis by Mechanism of Action / Driving Force
14.2.1.1.11. Analysis by Type of Technology
14.2.1.1.12. Analysis by Availability of Connectivity Feature
14.2.1.1.13. Analysis by Type of Compatible Drug
14.2.1.1.14. Analysis by Compatibility with High Viscosity Drugs
14.2.1.1.15. Analysis by Therapeutic Area
14.2.1.1.16. Most Active Players: Analysis by Number of Large Volume Wearable Injectors for Non-Insulin Drugs
14.2.1.2. Large Volume Wearable Injectors for Insulin Drugs
14.2.1.2.1. Analysis by Status of Development
14.2.1.2.2. Analysis by Type of Device
14.2.1.2.3. Analysis by Usability
14.2.1.2.4. Analysis by Type of Dose
14.2.1.2.5. Analysis by Mode of Drug Filling
14.2.1.2.6. Analysis by Container Volume (mL)
14.2.1.2.7. Analysis by Type of Diabetes
14.2.1.2.8. Analysis by Type of Combination Insulin
14.2.1.2.9. Analysis by Period of Use (Days)
14.2.1.2.10. Analysis by Type of Device Control Feature
14.2.1.2.11. Analysis by Availability of Interoperable Device
14.2.1.2.12. Analysis by Availability of Continuous Glucose Monitoring (CGM) / Blood Glucose Meters (BGM) System
14.2.1.2.13. Analysis by Availability of Automatic Insulin Delivery (AID) / Artificial Pancreas
14.2.1.2.14. Analysis by Type of Automated Insulin Delivery (AID) Feature
14.2.1.2.15. Analysis by Availability of Connectivity Feature
14.2.1.2.16. Analysis by Waterproof Capabilities
14.2.1.2.17. Most Active Players: Analysis by Number of Large Volume Wearable Injectors for Insulin Drugs
14.2.1.3. Large Volume Drug Device Combinations for Non-Insulin Drugs: Market Landscape
14.2.1.3.1. Analysis by Status of Development
14.2.1.3.2. Analysis by Type of Device
14.2.1.3.3. Analysis by Usability
14.2.1.3.4. Analysis by Type of Dose
14.2.1.3.5. Analysis by Type of Drug Container
14.2.1.3.6. Analysis by Mode of Drug Filling
14.2.1.3.7. Analysis by Container Volume (mL)
14.2.1.3.8. Analysis by Route of Administration
14.2.1.3.9. Analysis by Mode of Injection
14.2.1.3.10. Analysis by Type of Compatible Drug
14.2.1.3.11. Analysis by Mechanism of Action / Driving Force
14.2.1.3.12. Analysis by Type of Technology
14.2.1.3.13. Analysis by Therapeutic Area
14.2.1.3.14. Leading Players: Analysis by Number of Drug Device Combinations for Non-Insulin Drugs
14.2.2. Autoinjectors
14.2.2.1. Current Market Landscape
14.2.2.1.1. Analysis by Stage of Development
14.2.2.1.2. Analysis by Usability
14.2.2.1.3. Analysis by Type of Primary Drug Container
14.2.2.1.4. Analysis by Requirement of Needle
14.2.2.1.5. Analysis by Volume of Container
14.2.2.1.6. Analysis by Type of Dose Delivered
14.2.2.1.7. Analysis by Route of Administration
14.2.2.1.8. Analysis by Type of Actuation Mechanism
14.2.2.1.9. Analysis by Type of Feedback Mechanism
14.2.2.1.10. Analysis by Availability of Connectivity Feature
14.2.2.1.11. Analysis by Target Indication
14.2.2.1.12. Analysis by Type of Molecule Delivered
14.2.2.1.13. Analysis by End User
14.2.2.1.14. Most Active Players: Analysis by Number of Autoinjectors
14.2.3. Pen Injectors
14.2.3.1. Current Market Landscape
14.2.3.1.1. Analysis by Type of Dose
14.2.3.1.2. Analysis by Storage Volume / Capacity
14.2.3.1.3. Analysis by Usability
14.2.3.1.4. Most Active Players: Analysis by Number of Devices
14.2.3.2. Drug Device Combination Products
14.2.4. Needle Free Injection System
14.2.4.1. Current Market Landscape
14.2.4.1.1. Analysis by Actuation Mechanism
14.2.4.1.2. Analysis by Route of Administration
14.2.4.1.3. Analysis by Type of Formulation Administered
14.2.4.1.4. Analysis by Type of Drug Delivered
14.2.4.1.5. Analysis by Therapeutic Area
14.2.4.1.6. Analysis by Usability
14.2.4.1.7. Analysis by Type of Formulation Administered and Actuation Mechanism
14.2.5. Novel Drug Reconstitution Delivery Systems
14.2.5.1. Current Market Landscape
14.2.5.1.1. Analysis by Type of Device
14.2.5.1.2. Analysis by Type of Chamber
14.2.5.1.3. Analysis by Type of Device and Type of Chamber
14.2.5.1.4. Analysis by Physical State of Drug
14.2.5.1.5. Analysis by Container Fabrication Material
14.2.5.1.6. Analysis by Volume of Container
14.2.5.1.7. Analysis by Drug Class
14.2.5.1.8. Analysis by Device Usability
14.2.5.1.9. Analysis by Container Fabrication Material and Device Usability
14.2.5.1.10. Analysis by Type of Pre-sterilized Devices
14.2.5.1.11. Analysis by Type of User-sterilized Devices
14.2.5.1.12. Analysis by Type of Sterilization Equipment Used
14.2.5.1.13. Most Active Players: Analysis by Number of Novel Drug Reconstitution Systems Manufactured
14.2.6. Prefilled Syringes
14.2.6.1. Current Market Landscape
14.2.6.1.1. Analysis by Type of Barrel Fabrication Material
14.2.6.1.2. Analysis by Number of Barrel Chambers
14.2.6.1.3. Analysis by Type of Needle System
14.2.6.1.4. Analysis by Volume of Syringe
14.2.6.1.5. Most Active Players: Analysis by Number of Prefilled Syringes
14.2.6.2. Drug Device Combination Products
14.2.7. Implants
14.2.7.1. Current Market Landscape
14.2.7.1.1. Analysis by Phase of Development
14.2.7.1.2. Analysis by Therapeutic Area
14.2.7.1.3. Analysis by Implant Material
14.2.7.1.4. Analysis by Treatment Duration
14.2.7.1.5. Analysis by Type of Delivery System
14.2.7.1.6. Most Active Players: Analysis by Number of Implants
14.2.7.2. Subcutaneous Implants Eluting Small Molecules

15. SUBCUTANEOUS DRUG DELIVERY SYSTEMS: PRODUCT COMPETITIVENESS ANALYSIS
15.1. Chapter Overview
15.2. Large Volume Wearable Injectors
15.2.1. Assumptions and Key Parameters
15.2.2. Methodology
15.2.3. Product Competitiveness Analysis: Large Volume Wearable Injectors for Non-Insulin Drugs
15.2.3.1. Products Developed by Players in North America
15.2.3.2. Products Developed by Players in Europe
15.2.3.3. Products Developed by Players in Asia and Middle East and North Africa
15.2.4. Product Competitiveness Analysis: Large Volume Wearable Injectors for Insulin Drugs
15.2.4.1. Products Developed by Players in North America
15.2.4.2. Products Developed by Players in Europe
15.2.4.3. Products Developed by Players in Asia and Middle East and North Africa
15.2.5. Product Competitiveness Analysis: Large Volume Drug Device Combinations for Non-Insulin Drugs
15.2.5.1. Products Developed by Players in North America
15.2.5.2. Products Developed by Players in Europe
15.2.5.3. Products Developed by Players in Middle East and North Africa
15.3. Autoinjectors
15.3.1. Assumptions and Key Parameters
15.3.2. Methodology
15.3.3. Product Competitiveness Analysis: Autoinjectors
15.3.3.1. Disposable Autoinjectors
15.3.3.2. Reusable Autoinjectors
15.4. Needle-free Injection Systems
15.4.1. Assumptions and Key Parameters
15.4.2. Methodology
15.4.3. Product Competitiveness Analysis: Needle-free Injection Systems
15.4.3.1. Spring-based Needle-free Injection Systems
15.4.3.2. Gas-powered Needle-free Injection Systems
15.4.3.3. Other Needle-free Injection Systems
15.5. Prefilled Syringes
15.5.1. Assumptions and Key Parameters
15.5.2. Methodology
15.5.3. Product Competitiveness Analysis: Prefilled Syringes
15.5.3.1. Glass Barrel Prefilled Syringes
15.5.3.2. Plastic Barrel Prefilled Syringes

16. SWOT ANALYSIS
16.1. Chapter Overview
16.2. Comparison of SWOT Factors
16.2.1. Strengths
16.2.2. Weaknesses
16.2.3. Opportunities
16.2.4. Threats

17. GLOBAL APPROVED SUBCUTANEOUS BIOLOGICS MARKET
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Global Approved Subcutaneous Biologics Market, till 2035
17.3.1. Roots Analysis Perspective on Market Growth
17.3.2. Scenario Analysis
17.3.2.1. Conservative Scenario
17.3.2.2. Optimistic Scenario
17.4. Key Market Segmentations

18. APPROVED SUBCUTANEOUS BIOLOGICS MARKET, BY TYPE OF BIOLOGIC
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Approved Subcutaneous Biologics Market: Distribution by Type of Biologic, Current year and 2035
18.3.1. Approved Subcutaneous Biologics Market for Antibodies, till 2035
18.3.2. Approved Subcutaneous Biologics Market for Proteins, till 2035
18.3.3. Approved Subcutaneous Biologics Market for Nucleotides, till 2035
18.4. Data Triangulation and Validation

19. APPROVED SUBCUTANEOUS BIOLOGICS MARKET, BY TYPE OF THERAPY
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Approved Subcutaneous Biologics Market: Distribution by Type of Therapy, Current year and 2035
19.3.1. Approved Subcutaneous Biologics Market for Monotherapy, till 2035
19.3.2. Approved Subcutaneous Biologics Market for Combination Therapy, till 2035
19.3.3. Approved Subcutaneous Biologics Market for Both Monotherapy and Combination Therapies, till 2035
19.4. Data Triangulation and Validation

20. APPROVED SUBCUTANEOUS BIOLOGICS MARKET, BY METHOD OF ADMINISTRATION
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Approved Subcutaneous Biologics Market: Distribution by Method of Administration, Current year and 2035
20.3.1. Approved Subcutaneous Biologics Market for Administration via Injection, till 2035
20.3.2. Approved Subcutaneous Biologics Market for Administration via Infusion, till 2035
20.3.3. Approved Subcutaneous Biologics Market for Administration via Both Injection and Infusion, till 2035
20.4. Data Triangulation and Validation

21. APPROVED SUBCUTANEOUS BIOLOGICS MARKET, BY THERAPEUTIC AREA
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Approved Subcutaneous Biologics Market: Distribution by Therapeutic Area, Current year and 2035
21.3.1. Approved Subcutaneous Biologics Market for Autoimmune Disorders, till 2035
21.3.2. Approved Subcutaneous Biologics Market for Metabolic Disorders, till 2035
21.3.3. Approved Subcutaneous Biologics Market for Oncological Disorders, till 2035
21.3.4. Approved Subcutaneous Biologics Market for Hematological Disorders, till 2035
21.3.5. Approved Subcutaneous Biologics Market for Inflammatory Disorders, till 2035
21.3.6. Approved Subcutaneous Biologics Market for Neurological Disorders, till 2035
21.3.7. Approved Subcutaneous Biologics Market for Bone Disorders, till 2035
21.3.8. Approved Subcutaneous Biologics Market for Other Disorders, till 2035
21.4. Data Triangulation and Validation

22. APPROVED SUBCUTANEOUS BIOLOGICS MARKET, BY GEOGRAPHICAL REGIONS
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Approved Subcutaneous Biologics Market: Distribution by Geographical Regions, Current year and 2035
22.3.1. Approved Subcutaneous Biologics Market in North America, till 2035
22.3.2. Approved Subcutaneous Biologics Market in Europe, till 2035
22.3.3. Approved Subcutaneous Biologics Market in Asia-Pacific, till 2035
22.3.4. Approved Subcutaneous Biologics Market in Middle East and North Africa, till 2035
22.3.5. Approved Subcutaneous Biologics Market in Latin America, till 2035
22.4. Penetration-Growth (P-G) Matrix
22.5. Data Triangulation and Validation

23. APPROVED SUBCUTANEOUS BIOLOGICS MARKET, SALES FORECAST OF DRUGS
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Drug-wise Sales Forecast
23.3.1. Actemra® / RoActemra®
23.3.2. Acthar® Gel / ACTHar
23.3.3. AIMOVIG®
23.3.4. AJOVY®
23.3.5. AMVUTTRA®
23.3.6. Aranesp® / NESP®
23.3.7. Basaglar® / Abasaglar
23.3.8. BENLYSTA®
23.3.9. Betaseron® / Betaferon® / EXTAVIA®
23.3.10. CABLIVI®
23.3.11. CIMZIA®
23.3.12. COSENTYX®
23.3.13. CRYSVITA®
23.3.14. DARZALEX FASPRO® / DARZALEX® SC
23.3.15. DUPIXENT®
23.3.16. EMGALITY®
23.3.17. Enbrel®
23.3.18. ENSPRYNG®
23.3.19. ENTYVIO®
23.3.20. Epogen® / Procrit® / Eprex®
23.3.21. EVENITY®
23.3.22. FASENRA®
23.3.23. FIASP®
23.3.24. Forteo® / Forsteo®
23.3.25. GATTEX® / Revestive®
23.3.26. Genotropin®
23.3.27. GIVLAARI®
23.3.28. G-LASTA® / Peglasta® / Neulasta® / GRAN®
23.3.29. Gonal-F®
23.3.30. HAEGARDA®
23.3.31. HEMLIBRA®
23.3.32. Herceptin® SC / HERCEPTIN™ HYLECTA
23.3.33. Hizentra®
23.3.34. Humalog®
23.3.35. HUMIRA®
23.3.36. Humulin®
23.3.37. ILARIS®
23.3.38. Kesimpta®
23.3.39. KEVZARA®
23.3.40. KINERET®
23.3.41. LANTUS®
23.3.42. LEQVIO®
23.3.43. Mircera®
23.3.44. MOUNJARO®
23.3.45. NPLATE®
23.3.46. Nucala®
23.3.47. ORENCIA®
23.3.48. OXLUMO®
23.3.49. PALYNZIQ®
23.3.50. Phesgo®
23.3.51. PLEGRIDY®
23.3.52. PRALUENT®
23.3.53. Prolia® / Pralia®
23.3.54. Rebif®
23.3.55. REBLOZYL®
23.3.56. REKOVELLE®
23.3.57. Repatha®
23.3.58. RITUXAN HYCELA® / MabThera® SC
23.3.59. RYZODEG® 70/30 SC
23.3.60. Saizen®
23.3.61. Saxenda®
23.3.62. SIMPONI®
23.3.63. Skyrizi®
23.3.64. SOLIQUA® 100/33
23.3.65. STELARA®
23.3.66. Strensiq®
23.3.67. TAKHZYRO®
23.3.68. Taltz®
23.3.69. Tecentriq®
23.3.70. TEGSEDI®
23.3.71. TEZSPIRE®
23.3.72. Toujeo®
23.3.73. TREMFYA®
23.3.74. TRESIBA®
23.3.75. Trulicity®
23.3.76. Tysabri®
23.3.77. Ultomiris®
23.3.78. Victoza®
23.3.79. Voxzogo®
23.3.80. VYVGART® Hytrulo
23.3.81. WAINUA™
23.3.82. Xgeva® / RANMARK®
23.3.83. XOLAIR®
23.3.84. XULTOPHY®
23.3.85. ZEPBOUND®

24. APPROVED SUBCUTANEOUS BIOLOGICS MARKET, BY LEADING PLAYERS

25. GLOBAL SUBCUTANEOUS BIOLOGICS FORMULATION TECHNOLOGIES MARKET
25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. Global Subcutaneous Biologics Formulation Technologies Market, till 2035
25.3.1. Roots Analysis Perspective on Market Growth
25.3.2. Scenario Analysis
25.3.2.1. Conservative Scenario
25.3.2.2. Optimistic Scenario
25.4. Key Market Segmentations

26. SUBCUTANEOUS BIOLOGICS FORMULATION TECHNOLOGIES MARKET, BY FUNDAMENTAL PRINCIPLE
26.1. Chapter Overview
26.2. Key Assumptions and Methodology
26.3. Subcutaneous Biologics Formulation Technologies Market: Distribution by Fundamental Principle, Current year and 2035
26.3.1. Subcutaneous Biologics Formulation Technologies Market for Encapsulation Principle, till 2035
26.3.2. Subcutaneous Biologics Formulation Technologies Market for Complex Formation Principle, till 2035
26.3.3. Subcutaneous Biologics Formulation Technologies Market for Conjugation Principle, till 2035
26.3.4. Subcutaneous Biologics Formulation Technologies Market for Amino Acid Interaction Principle, till 2035
26.3.5. Subcutaneous Biologics Formulation Technologies Market for Other Principles, till 2035
26.4. Data Triangulation and Validation

27. SUBCUTANEOUS BIOLOGICS FORMULATION TECHNOLOGIES MARKET, BY END USER
27.1. Chapter Overview
27.2. Key Assumptions and Methodology
27.3. Subcutaneous Biologics Formulation Technologies Market: Distribution by Type of End User, Current year and 2035
27.3.1. Subcutaneous Biologics Formulation Technologies for Pharmaceutical and Biopharmaceutical Companies, till 2035
27.3.2. Subcutaneous Biologics Formulation Technologies for Biotechnology Companies, till 2035
27.3.3. Subcutaneous Biologics Formulation Technologies for MedTech Companies, till 2035
27.3.4. Subcutaneous Biologics Formulation Technologies for Contract Drug Manufacturing Organizations, till 2035
27.3.5. Subcutaneous Biologics Formulation Technologies for Educational Institutes, till 2035
27.3.6. Subcutaneous Biologics Formulation Technologies for Medical Equipment Manufacturers, till 2035
27.3.7. Subcutaneous Biologics Formulation Technologies for Other End Users, till 2035
27.4. Data Triangulation and Validation

28. SUBCUTANEOUS BIOLOGICS FORMULATION TECHNOLOGIES MARKET, BY THERAPEUTIC AREA
28.1. Chapter Overview
28.2. Key Assumptions and Methodology
28.3. Subcutaneous Biologics Formulation Technologies Market: Distribution by Therapeutic Area, Current year and 2035
28.3.1. Subcutaneous Biologics Formulation Technologies for Oncological Disorders, till 2035
28.3.2. Subcutaneous Biologics Formulation Technologies for Metabolic Disorders, till 2035
28.3.3. Subcutaneous Biologics Formulation Technologies for Ocular Disorders, till 2035
28.3.4. Subcutaneous Biologics Formulation Technologies for Infectious Diseases, till 2035
28.3.5. Subcutaneous Biologics Formulation Technologies for Autoimmune Disorders, till 2035
28.3.6. Subcutaneous Biologics Formulation Technologies for Neurological Disorders, till 2035
28.3.7. Subcutaneous Biologics Formulation Technologies for Immunological Disorders, till 2035
28.3.8. Subcutaneous Biologics Formulation Technologies for Other Disorders, till 2035
28.4. Data Triangulation and Validation

29. SUBCUTANEOUS BIOLOGICS FORMULATION TECHNOLOGIES MARKET, BY KEY GEOGRAPHICAL REGIONS
29.1. Chapter Overview
29.2. Key Assumptions and Methodology
29.3. Subcutaneous Biologics Formulation Technologies Market: Distribution by Key Geographical Regions, Current year and 2035
29.3.1. Subcutaneous Biologics Formulation Technologies Market in North America, till 2035
29.3.2. Subcutaneous Biologics Formulation Technologies Market in Europe, till 2035
29.3.3. Subcutaneous Biologics Formulation Technologies Market in Asia-Pacific, till 2035
29.4. Penetration-Growth (P-G) Matrix
29.5. Data Triangulation and Validation

30. SUBCUTANEOUS BIOLOGICS FORMULATION TECHNOLOGIES MARKET, BY TYPE OF PAYMENT METHOD EMPLOYED
30.1. Chapter Overview
30.2. Key Assumptions and Methodology
30.3. Subcutaneous Biologics Formulation Technologies Market: Distribution by Type of Payment Method Employed, Current year and 2035
30.3.1. Subcutaneous Biologics Formulation Technologies Market based on Milestone Payments, till 2035
30.3.2. Subcutaneous Biologics Formulation Technologies Market based on Upfront Payments, till 2035
30.4. Data Triangulation and Validation

31. SUBCUTANEOUS BIOLOGICS FORMULATION TECHNOLOGIES MARKET, BY LEADING PLAYERS

32. SUBCUTANEOUS DRUG DELIVERY SYSTEM: MARKET FORECAST
32.1. Chapter Overview
32.2. Global Large Volume Wearable Injectors Market
32.2.1. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, till 2035 (By Value)
32.2.2. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, till 2035 (By Volume)
32.2.3. Global Large Volume Wearable Injectors Market for Insulin Drugs, till 2035 (By Value)
32.2.4. Global Large Volume Wearable Injectors Market for Insulin Drugs, till 2035 (By Volume)
32.2.5. Global Autoinjectors Market
32.2.6. Global Needle-free Injection Systems Market
32.2.7. Global Novel Drug Reconstitution Systems Market
32.2.8. Global Prefilled Syringes Market

33. CONCLUSION

34. EXECUTIVE INSIGHTS
34.1. Chapter Overview
34.2. Company A 
34.2.1. Company Snapshot
34.2.2. Interview Transcript: Founder and Chief Executive Officer
34.3. Company B
34.3.1. Company Snapshot
34.3.2. Interview Transcript: Founder and Chief Technology Officer
34.4. Company C
34.4.1. Company Snapshot
34.4.2. Interview Transcript: Chief Executive Officer & Founder
34.5. Company D
34.5.1. Company Snapshot
34.5.2. Interview Transcript: Chief Executive Officer
34.6. Company E
34.6.1. Company Snapshot
34.6.2. Interview Transcript: Chief Executive Officer
34.7. Company F
34.7.1. Company Snapshot
34.7.2. Interview Transcript: Chief Technical Officer
34.8. Company G
34.8.1. Company Snapshot
34.8.2. Interview Transcript: Menachem Zucker, Vice President and Chief Scientist
34.9. Company H 
34.9.1. Company Snapshot
34.9.2. Interview Transcript: Jesse Fourt, Senior Portfolio Director
34.10. Company I 
34.10.1. Company Snapshot
34.10.2. Interview Transcript: Managing Director
34.11. Company J
34.11.1. Company Snapshot
34.11.2. Interview Transcript: Communication Leader
34.12. Company K
34.12.1. Company Snapshot
34.12.2. Interview Transcript: Former Founder and Chief Scientific Officer, Former Vice President (Product Development) and Former Sr. Scientist Formulation
34.13. Company H
34.13.1. Company Snapshot
34.13.2. Interview Transcript: Former Chief Commercial Officer
34.14. Company I
34.14.1. Company Snapshot
34.14.2. Interview Transcript: Anonymous
34.15. Company J
34.15.1. Company Snapshot
34.15.2. Interview Transcript: Anonymous

35. APPENDIX 1: TABULATED DATA

36. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
 
LIST OF FIGURES

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Key Market Segmentation
Figure 3.3 Market Dynamics: Robust Quality Control
Figure 4.1 Lessons Learnt from Past Recessions
Figure 5.1 Executive Summary: Approved Subcutaneous Biologics Landscape
Figure 5.2 Executive Summary: Clinical-stage Subcutaneous Biologics Landscape
Figure 5.3 Executive Summary: Subcutaneous Formulation Technology Landscape
Figure 5.4 Executive Summary: Partnerships and Collaborations (Subcutaneous Formulation Technology)
Figure 5.5 Executive Summary: Approved Subcutaneous Biologics Market Forecast and Opportunity Analysis
Figure 5.6 Executive Summary: Subcutaneous Biologics Formulation Technologies Market Forecast and Opportunity Analysis
Figure 6.1 Types of Biologically Derived Therapeutics
Figure 6.2 Conversion from Intravenous to Subcutaneous Formulation: Key Points for Pharma Companies
Figure 6.3 Process of Developing a Subcutaneous Formulation from Intravenous Product
Figure 6.4 Subcutaneous Drug Delivery: Possible Routes of Administration for Large-Dose Biologics
Figure 6.5 Landscape of Large Volume Subcutaneous Drug Delivery Devices
Figure 6.6 Steps Involved in Subcutaneous Drug Delivery
Figure 7.1 Approved Subcutaneous Biologics: Distribution by Initial Approval Year
Figure 7.2 Approved Subcutaneous Biologics: Distribution by Type of Biologic
Figure 7.3 Approved Subcutaneous Biologics: Distribution by Initial Approval Year and Type of Biologic
Figure 7.4 Approved Subcutaneous Biologics: Distribution by Type of Therapy
Figure 7.5 Approved Subcutaneous Biologics: Distribution by Route of Administration
Figure 7.6 Approved Subcutaneous Biologics: Distribution by Method of Administration
Figure 7.7 Approved Subcutaneous Biologics: Distribution by Dosing Frequency
Figure 7.8 Approved Subcutaneous Biologics: Distribution by Concentration of Dose
Figure 7.9 Approved Subcutaneous Biologics: Distribution by Target Disease Indication
Figure 7.10 Approved Subcutaneous Biologics: Distribution by Therapeutic Area
Figure 7.11 Approved Subcutaneous Biologics: Distribution by Type of Drug Delivery Device
Figure 7.12 Approved Subcutaneous Biologics: Distribution by Year of Establishment
Figure 7.13 Approved Subcutaneous Biologics: Distribution by Company Size
Figure 7.14 Approved Subcutaneous Biologics: Distribution by Location of Headquarters (Region)
Figure 7.15 Approved Subcutaneous Biologics: Distribution by Location of Headquarters (Country)
Figure 7.16 Approved Subcutaneous Biologics: Distribution by Company Size and Location of Headquarters (Region)
Figure 7.17 Most Active Developers: Distribution by Number of Approved Drugs
Figure 8.1 BENLYSTA (Roche): Development History
Figure 8.2 BENLYSTA (Roche): Success Protocol Analysis
Figure 8.3 BESREMi (PharmaEssentia): Development History
Figure 8.4 BESREMi (PharmaEssentia): Success Protocol Analysis
Figure 8.5 COSENTYX (Novartis): Development History
Figure 8.6 COSENTYX (Novartis): Success Protocol Analysis
Figure 8.7 DARZALEX FASPRO (Halozyme): Development History
Figure 8.8 DARZALEX FASPRO (Halozyme): Success Protocol Analysis
Figure 8.9 DUPIXENT (Regeneron Pharmaceuticals): Development History
Figure 8.10 DUPIXENT (Regeneron Pharmaceuticals): Success Protocol Analysis
Figure 8.11 Enbrel (Amgen): Development History
Figure 8.12 Enbrel (Amgen): Success Protocol Analysis
Figure 8.13 HEMLIBRA (Roche): Development History
Figure 8.14 HEMLIBRA (Roche): Success Protocol Analysis
Figure 8.15 Prolia / Pralia (Amgen): Development History
Figure 8.16 Prolia / Pralia (Amgen): Success Protocol Analysis
Figure 8.17 STELARA (Janssen Biotech): Development History
Figure 8.18 STELARA (Janssen Biotech): Success Protocol Analysis
Figure 8.19 Trulicity (Eli Lilly): Development History
Figure 8.20 Trulicity (Eli Lilly): Success Protocol Analysis
Figure 8.21 Success Protocol Analysis: Conclusion
Figure 9.1 Clinical-stage Subcutaneous Biologics: Distribution by Status of Development
Figure 9.2 Clinical-stage Subcutaneous Biologics: Distribution by Type of Biologic
Figure 9.3 Clinical-stage Subcutaneous Biologics: Distribution by Stage of Development and Type of Biologic
Figure 9.4 Clinical-stage Subcutaneous Biologics: Distribution by Type of Therapy
Figure 9.5 Clinical-stage Subcutaneous Biologics: Distribution by Mechanism of Action
Figure 9.6 Clinical-stage Subcutaneous Biologics: Distribution by Dosing Frequency
Figure 9.7 Clinical-stage Subcutaneous Biologics: Distribution by Drug Designation
Figure 9.8 Clinical-stage Subcutaneous Biologics: Distribution by Target Disease Indication
Figure 9.9 Clinical-stage Subcutaneous Biologics: Distribution by Therapeutic Area
Figure 9.10 Clinical-stage Subcutaneous Biologics: Distribution by Stage of Development and Therapeutic Area
Figure 9.11 Clinical-stage Subcutaneous Biologics: Distribution by Therapeutic Area and Type of Biologic
Figure 9.12 Clinical-stage Subcutaneous Biologics: Distribution by Year of Establishment
Figure 9.13 Clinical-stage Subcutaneous Biologics: Distribution by Company Size
Figure 9.14 Clinical-stage Subcutaneous Biologics: Distribution by Location of Headquarters (Region)
Figure 9.15 Clinical-stage Subcutaneous Biologics: Distribution by Company Size and Location of Headquarters (Region)
Figure 9.16 Most Active Developers: Distribution by Number of Clinical-stage Drugs
Figure 10.1 Subcutaneous Formulation Technologies: Distribution by Fundamental Principle
Figure 10.2 Subcutaneous Formulation Technologies: Distribution by Type of Molecule
Figure 10.3 Subcutaneous Formulation Technologies: Distribution by Route of Administration
Figure 10.4 Subcutaneous Formulation Technologies: Distribution by Type of Molecule and Route of Administration
Figure 10.5 Subcutaneous Formulation Technologies: Distribution by Therapeutic Area
Figure 10.6 Subcutaneous Formulation Technologies: Distribution by Key Characteristics
Figure 10.7 Subcutaneous Formulation Technology Developers: Distribution by Year of Establishment
Figure 10.8 Subcutaneous Formulation Technology Developers: Distribution by Company Size
Figure 10.9 Subcutaneous Formulation Technology Developers: Distribution by Location of Headquarters (Region)
Figure 10.10 Subcutaneous Formulation Technology Developers: Distribution by Company Size and Location of Headquarters (Region)
Figure 11.1 Technology Competitiveness Analysis: Subcutaneous Formulation Technology Developed by Companies based in North America (Peer Group I)
Figure 11.2 Technology Competitiveness Analysis: Subcutaneous Formulation Technology Developed by Companies based in Europe (Peer Group II)
Figure 11.3 Technology Competitiveness Analysis: Subcutaneous Formulation Technology Developed by Companies based in Asia-Pacific (Peer Group III)
Figure 12.1 Pacira BioSciences: Annual Revenues, since 2020 (USD Million)
Figure 12.2 Xeris Biopharma: Annual Revenues, since 2020 (USD Million)
Figure 12.3 Adocia: Annual Revenues, since 2019 (EUR Million)
Figure 12.4 Ascendis Pharma: Annual Revenues, since 2020 (EUR Million)
Figure 12.5 Foresee Pharmaceuticals: Annual Revenues, since 2020 (TWD Million)
Figure 13.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 13.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 13.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 13.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 13.5 Partnerships and Collaborations: Distribution by Location of Headquarters of Partner
Figure 13.6 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 13.7 Most Active Players: Distribution by Number of Partnerships
Figure 13.8 Partnerships and Collaborations: Distribution by Region
Figure 13.9 Partnerships and Collaborations: Distribution by International and Local Agreements
Figure 13.10 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Figure 14.1 Different Types of Subcutaneous Drug Delivery Systems
Figure 14.2 Large Volume Wearable Injectors: Distribution by Type of Device (By Drug Administered)
Figure 14.3 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Status of Development
Figure 14.4 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Device
Figure 14.5 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Usability
Figure 14.6 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Dose
Figure 14.7 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Drug Container
Figure 14.8 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Mode of Drug Filling
Figure 14.9 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Container Volume (mL)
Figure 14.10 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Route of Administration
Figure 14.11 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Mode of Injection
Figure 14.12 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Mechanism of Action / Driving Force
Figure 14.13 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Technology
Figure 14.14 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Availability of Connectivity Feature
Figure 14.15 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Compatible Drug
Figure 14.16 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Compatibility with High Viscosity Drugs
Figure 14.17 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Therapeutic Area
Figure 14.18 Most Active Players: Distribution by Number of Large Volume Wearable Injectors for Non-Insulin Drugs
Figure 14.19 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Status of Development
Figure 14.20 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type of Device
Figure 14.21 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Usability
Figure 14.22 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type of Dose
Figure 14.23 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Mode of Drug Filling
Figure 14.24 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Container Volume (mL)
Figure 14.25 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type of Diabetes
Figure 14.26 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type of Combination Insulin
Figure 14.27 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Period of use (Days)
Figure 14.28 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type of Device Control Feature
Figure 14.29 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Interoperable Device
Figure 14.30 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Continuous Glucose Monitoring (CGM) / Blood Glucose Meters (BGM) System
Figure 14.31 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Automatic Insulin Delivery (AID) / Artificial Pancreas
Figure 14.32 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type of Automated Insulin Delivery (AID) Feature
Figure 14.33 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Connectivity Feature
Figure 14.34 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Waterproof Capabilities
Figure 14.35 Leading Players: Analysis by Number of Large Volume Wearable Injectors for Insulin
Figure 14.36 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Status of Development
Figure 14.37 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Device
Figure 14.38 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Usability
Figure 14.39 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Dose
Figure 14.40 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Drug Container
Figure 14.41 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Mode of Drug Filling
Figure 14.42 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Container Volume (mL)
Figure 14.43 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Route of Administration
Figure 14.44 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Mode of Injection
Figure 14.45 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Compatible Drug
Figure 14.46 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Mechanism of Action / Driving Force
Figure 14.47 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Technology
Figure 14.48 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Therapeutic Area
Figure 14.49 Most Active Players: Distribution by Number of Drug Device Combinations for Non-Insulin Drugs
Figure 14.50 Autoinjectors: Distribution by Stage of Development
Figure 14.51 Autoinjectors: Distribution by Usability
Figure 14.52 Autoinjectors: Distribution by Type of Primary Drug Container
Figure 14.53 Autoinjectors: Distribution by Requirement of Needle
Figure 14.54 Autoinjectors: Distribution by Volume of Container
Figure 14.55 Autoinjectors: Distribution by Type of Dose Delivered
Figure 14.56 Autoinjectors: Distribution by Route of Administration
Figure 14.57 Autoinjectors: Distribution by Type of Actuation Mechanism
Figure 14.58 Autoinjectors: Distribution by Type of Feedback Mechanism
Figure 14.59 Autoinjectors: Distribution by Availability of Connectivity Feature
Figure 14.60 Autoinjectors: Distribution by Target Indication
Figure 14.61 Autoinjectors: Distribution by Type of Molecule Delivered
Figure 14.62 Autoinjectors: Distribution by End User
Figure 14.63 Most Active Players: Distribution by Number of Autoinjectors
Figure 14.64 Pen Injectors: Distribution by Type of Dose
Figure 14.65 Pen Injectors: Distribution by Storage Volume / Capacity (in ml)
Figure 14.66 Pen Injectors: Distribution by Usability
Figure 14.67 Most Active Players: Distribution by Number of Pen Injectors
Figure 14.68 Needle-free Injection Systems: Distribution by Type of Actuation Mechanism
Figure 14.69 Needle-free Injection Systems: Distribution by Route of Administration
Figure 14.70 Needle-free Injection Systems: Distribution by Type of Formulation Administered
Figure 14.71 Needle-free Injection Systems: Distribution by Type of Drug Delivered
Figure 14.72 Needle-free Injection Systems: Distribution by Therapeutic Area
Figure 14.73 Needle-free Injection Systems: Distribution by Usability
Figure 14.74 Needle-free Injection Systems: Distribution by Type of Formulation Administered and Actuation Mechanism
Figure 14.75 Novel Drug Reconstitution Systems: Distribution by Type of Device
Figure 14.76 Novel Drug Reconstitution Systems: Distribution by Type of Chamber
Figure 14.77 Novel Drug Reconstitution Systems: Distribution by Type of Device and Type of Chamber
Figure 14.78 Novel Drug Reconstitution Systems: Distribution by Physical State of Drug
Figure 14.79 Novel Drug Reconstitution Systems: Distribution by Container Fabrication Material
Figure 14.80 Novel Drug Reconstitution Systems: Distribution by Volume of Container (mL)
Figure 14.81 Novel Drug Reconstitution Systems: Distribution by Drug Class
Figure 14.82 Novel Drug Reconstitution Systems: Distribution by Device Usability
Figure 14.83 Novel Drug Reconstitution Systems: Distribution by Container Fabrication Material and Device Usability
Figure 14.84 Novel Drug Reconstitution Systems: Distribution by Type of Pre-sterilized Device
Figure 14.85 Novel Drug Reconstitution Systems: Distribution by Type of User-sterilized Device
Figure 14.86 Novel Drug Reconstitution Systems: Distribution by Type of Type of Sterilization Equipment Used
Figure 14.87 Most Active Players: Distribution by Number of Novel Drug Reconstitution Systems Manufactured
Figure 14.88 Prefilled Syringes: Distribution by Type of Barrel Fabrication Material
Figure 14.89 Prefilled Syringes: Distribution by Number of Barrel Chambers
Figure 14.90 Prefilled Syringes: Distribution by Type of Needle System
Figure 14.91 Prefilled Syringes: Distribution by Volume of Syringe
Figure 14.92 Most Active Players: Distribution by Number of Prefilled Syringes
Figure 14.93 Implants: Distribution by Phase of Development
Figure 14.94 Implants: Distribution by Therapeutic Area
Figure 14.95 Implants: Distribution by Implant Material
Figure 14.96 Implants: Distribution by Treatment Duration
Figure 14.97 Implants: Distribution by Type of Delivery System
Figure 14.98 Most Active Players: Distribution by Number of Implants
Figure 15.1 Product Competitiveness Analysis: Large Volume Wearable Injectors Developed by Players in North America for Non-Insulin Drugs
Figure 15.2 Product Competitiveness Analysis: Large Volume Wearable Injectors Developed by Players in Europe for Non-Insulin Drugs
Figure 15.3 Product Competitiveness Analysis: Large Volume Wearable Injectors Developed by Players in Asia and MENA for Non-Insulin Drugs
Figure 15.4 Product Competitiveness Analysis: Large Volume Wearable Injectors Developed by Players in North America for Insulin Drugs
Figure 15.5 Product Competitiveness Analysis: Large Volume Wearable Injectors Developed by Players in Europe for Insulin Drugs
Figure 15.6 Product Competitiveness Analysis: Large Volume Wearable Injectors Developed by Players in Asia and MENA for Insulin Drugs
Figure 15.7 Product Competitiveness Analysis: Large Volume Wearable Injectors Developed by Players in North America for Combination Products
Figure 15.8 Product Competitiveness Analysis: Large Volume Wearable Injectors Developed by Players in Europe for Combination Product
Figure 15.9 Product Competitiveness Analysis: Large Volume Wearable Injectors Developed by Players in MENA for Combination Products
Figure 15.10 Product Competitiveness Analysis: Disposable Autoinjectors
Figure 15.11 Product Competitiveness Analysis: Reusable Autoinjectors
Figure 15.12 Product Competitiveness Analysis: Spring-based Needle-free Injection Systems
Figure 15.13 Product Competitiveness Analysis: Gas-powered Needle-free Injection Systems
Figure 15.14 Product Competitiveness Analysis: Other Needle-free Injection Systems
Figure 15.15 Product Competitiveness Analysis: Glass Barrel Prefilled Syringes
Figure 15.16 Product Competitiveness Analysis: Plastic Barrel Prefilled Syringes
Figure 16.1 Subcutaneous Biologics SWOT Analysis: Overview
Figure 16.2 SWOT Analysis: Harvey Ball Analysis
Figure 16.3 Number of Biologics Approved by the USFDA, 2001-2021
Figure 17.1 Global Approved Subcutaneous Biologics Market, till 2035 (USD Billion)
Figure 17.2 Global Approved Subcutaneous Biologics Market, till 2035: Conservative Scenario (USD Billion)
Figure 17.3 Global Approved Subcutaneous Biologics Market, till 2035: Optimistic Scenario (USD Billion)
Figure 18.1 Approved Subcutaneous Biologics Market: Distribution by Type of Biologic, Current year and 2035
Figure 18.2 Approved Subcutaneous Biologics Market for Antibodies, till 2035 (USD Billion)
Figure 18.3 Approved Subcutaneous Biologics Market for Proteins, till 2035 (USD Billion)
Figure 18.4 Approved Subcutaneous Biologics Market for Nucleotides, till 2035 (USD Billion)
Figure 19.1 Approved Subcutaneous Biologics Market: Distribution by Type of Therapy, Current year and 2035
Figure 19.2 Approved Subcutaneous Biologics Market for Monotherapy, till 2035 (USD Billion)
Figure 19.3 Approved Subcutaneous Biologics Market for Combination Therapy, till 2035 (USD Billion)
Figure 19.4 Approved Subcutaneous Biologics Market for Both Monotherapy and Combination Therapy, till 2035 (USD Billion)
Figure 20.1 Approved Subcutaneous Biologics Market: Distribution by Method of Administration, Current year and 2035
Figure 20.2 Approved Subcutaneous Biologics Market for Administration via Injection, till 2035 (USD Billion)
Figure 20.3 Approved Subcutaneous Biologics Market for Administration via Infusion, till 2035 (USD Billion)
Figure 20.4 Approved Subcutaneous Biologics Market for Administration via Both Injection and Infusion, till 2035 (USD Billion)
Figure 21.1 Approved Subcutaneous Biologics Market: Distribution by Therapeutic Area, Current year and 2035
Figure 21.2 Approved Subcutaneous Biologics Market for Autoimmune Disorders, till 2035 (USD Billion)
Figure 21.3 Approved Subcutaneous Biologics Market for Metabolic Disorders, till 2035 (USD Billion)
Figure 21.4 Approved Subcutaneous Biologics Market for Oncological Disorders, till 2035 (USD Billion)
Figure 21.5 Approved Subcutaneous Biologics Market for Hematological Disorders, till 2035 (USD Billion)
Figure 21.6 Approved Subcutaneous Biologics Market for Inflammatory Disorders, till 2035 (USD Billion)
Figure 21.7 Approved Subcutaneous Biologics Market for Neurological Disorders, till 2035 (USD Billion)
Figure 21.8 Approved Subcutaneous Biologics Market for Bone Disorders, till 2035 (USD Billion)
Figure 21.9 Approved Subcutaneous Biologics Market for Other Disorders, till 2035 (USD Billion)
Figure 22.1 Approved Subcutaneous Biologics Market: Distribution by Geographical Regions, Current year and 2035
Figure 22.2 Approved Subcutaneous Biologics Market in North America, till 2035 (USD Billion)
Figure 22.3 Approved Subcutaneous Biologics Market in Europe, till 2035 (USD Billion)
Figure 22.4 Approved Subcutaneous Biologics Market in Asia-Pacific, till 2035 (USD Billion)
Figure 22.5 Approved Subcutaneous Biologics Market in Middle East and North Africa, till 2035 (USD Billion)
Figure 22.6 Approved Subcutaneous Biologics Market in Latin America, till 2035 (USD Billion)
Figure 22.7 Penetration-Growth (P-G) Matrix: Geographical Regions
Figure 23.1 Approved Subcutaneous Biologics Market: Actemra / RoActemra Sales Forecast, till 2035 (USD Billion)
Figure 23.2 Approved Subcutaneous Biologics Market: Acthar Gel / ACTHar Sales Forecast, till 2035 (USD Billion)
Figure 23.3 Approved Subcutaneous Biologics Market: AIMOVIG Sales Forecast, till 2035 (USD Billion)
Figure 23.4 Approved Subcutaneous Biologics Market: AJOVY Sales Forecast, till 2035 (USD Billion)
Figure 23.5 Approved Subcutaneous Biologics Market: AMVUTTRA Sales Forecast, till 2035 (USD Billion)
Figure 23.6 Approved Subcutaneous Biologics Market: ARANESP / NESP Sales Forecast, till 2035 (USD Billion)
Figure 23.7 Approved Subcutaneous Biologics Market: Basaglar / Abasaglar Sales Forecast, till 2035 (USD Billion)
Figure 23.8 Approved Subcutaneous Biologics Market: BENLYSTA Sales Forecast, till 2035 (USD Billion)
Figure 23.9 Approved Subcutaneous Biologics Market: Betaseron / Betaferon / EXTAVIA Sales Forecast, till 2035 (USD Billion)
Figure 23.10 Approved Subcutaneous Biologics Market: CABLIVI Sales Forecast, till 2035 (USD Billion)
Figure 23.11 Approved Subcutaneous Biologics Market: CIMZIA Sales Forecast, till 2035 (USD Billion)
Figure 23.12 Approved Subcutaneous Biologics Market: COSENTYX Sales Forecast, till 2035 (USD Billion)
Figure 23.13 Approved Subcutaneous Biologics Market: CRYSVITA Sales Forecast, till 2035 (USD Billion)
Figure 23.14 Approved Subcutaneous Biologics Market: DARZALEX FASPRO / DARZALEX SC Sales Forecast, till 2035 (USD Billion)
Figure 23.15 Approved Subcutaneous Biologics Market: DUPIXENT Sales Forecast, till 2035 (USD Billion)
Figure 23.16 Approved Subcutaneous Biologics Market: EMGALITY Sales Forecast, till 2035 (USD Billion)
Figure 23.17 Approved Subcutaneous Biologics Market: Enbrel Sales Forecast, till 2035 (USD Billion)
Figure 23.18 Approved Subcutaneous Biologics Market: ENSPRYNG Sales Forecast, till 2035 (USD Billion)
Figure 23.19 Approved Subcutaneous Biologics Market: ENTYVIO Sales Forecast, till 2035 (USD Billion)
Figure 23.20 Approved Subcutaneous Biologics Market: Epogen / Procrit / Eprex Sales Forecast, till 2035 (USD Billion)
Figure 23.21 Approved Subcutaneous Biologics Market: EVENITY Sales Forecast, till 2035 (USD Billion)
Figure 23.22 Approved Subcutaneous Biologics Market: FASENRA Sales Forecast, till 2035 (USD Billion)
Figure 23.23 Approved Subcutaneous Biologics Market: FIASP Sales Forecast, till 2035 (USD Billion)
Figure 23.24 Approved Subcutaneous Biologics Market: Forteo / Forsteo Sales Forecast, till 2035 (USD Billion)
Figure 23.25 Approved Subcutaneous Biologics Market: GATTEX / Revestive Sales Forecast, till 2035 (USD Billion)
Figure 23.26 Approved Subcutaneous Biologics Market: Genotropin Sales Forecast, till 2035 (USD Billion)
Figure 23.27 Approved Subcutaneous Biologics Market: GIVLAARI Sales Forecast, till 2035 (USD Billion)
Figure 23.28 Approved Subcutaneous Biologics Market: G-LASTA / Peglasta / Neulasta / GRAN Sales Forecast, till 2035 (USD Billion)
Figure 23.29 Approved Subcutaneous Biologics Market: Gonal-F Sales Forecast, till 2035 (USD Billion)
Figure 23.30 Approved Subcutaneous Biologics Market: HAEGARDA Sales Forecast, till 2035 (USD Billion)
Figure 23.31 Approved Subcutaneous Biologics Market: HEMLIBRA Sales Forecast, till 2035 (USD Billion)
Figure 23.32 Approved Subcutaneous Biologics Market: Herceptin SC / HERCEPTIN HYLECTA Sales Forecast, till 2035 (USD Billion)
Figure 23.33 Approved Subcutaneous Biologics Market: Hizentra Sales Forecast, till 2035 (USD Billion)
Figure 23.34 Approved Subcutaneous Biologics Market: Humalog Sales Forecast, till 2035 (USD Billion)
Figure 23.35 Approved Subcutaneous Biologics Market: HUMIRA Sales Forecast, till 2035 (USD Billion)
Figure 23.36 Approved Subcutaneous Biologics Market: Humulin Sales Forecast, till 2035 (USD Billion)
Figure 23.37 Approved Subcutaneous Biologics Market: ILARIS Sales Forecast, till 2035 (USD Billion)
Figure 23.38 Approved Subcutaneous Biologics Market: Kesimpta Sales Forecast, till 2035 (USD Billion)
Figure 23.39 Approved Subcutaneous Biologics Market: KEVZARA Sales Forecast, till 2035 (USD Billion)
Figure 23.40 Approved Subcutaneous Biologics Market: KINERET Sales Forecast, till 2035 (USD Billion)
Figure 23.41 Approved Subcutaneous Biologics Market: LANTUS Sales Forecast, till 2035 (USD Billion)
Figure 23.42 Approved Subcutaneous Biologics Market: LEQVIO Sales Forecast, till 2035 (USD Billion)
Figure 23.43 Approved Subcutaneous Biologics Market: Mircera Sales Forecast, till 2035 (USD Billion)
Figure 23.44 Approved Subcutaneous Biologics Market: MOUNJARO Sales Forecast, till 2035 (USD Billion)
Figure 23.45 Approved Subcutaneous Biologics Market: NPLATE Sales Forecast, till 2035 (USD Billion)
Figure 23.46 Approved Subcutaneous Biologics Market: Nucala Sales Forecast, till 2035 (USD Billion)
Figure 23.47 Approved Subcutaneous Biologics Market: ORENCIA Sales Forecast, till 2035 (USD Billion)
Figure 23.48 Approved Subcutaneous Biologics Market: OXLUMO Sales Forecast, till 2035 (USD Billion)
Figure 23.49 Approved Subcutaneous Biologics Market: PALYNZIQ Sales Forecast, till 2035 (USD Billion)
Figure 23.50 Approved Subcutaneous Biologics Market: Phesgo Sales Forecast, till 2035 (USD Billion)
Figure 23.51 Approved Subcutaneous Biologics Market: PLEGRIDY Sales Forecast, till 2035 (USD Billion)
Figure 23.52 Approved Subcutaneous Biologics Market: PRALUENT Sales Forecast, till 2035 (USD Billion)
Figure 23.53 Approved Subcutaneous Biologics Market: Prolia / Pralia Sales Forecast, till 2035 (USD Billion)
Figure 23.54 Approved Subcutaneous Biologics Market: Rebif Sales Forecast, till 2035 (USD Billion)
Figure 23.55 Approved Subcutaneous Biologics Market: REBLOZYL Sales Forecast, till 2035 (USD Billion)
Figure 23.56 Approved Subcutaneous Biologics Market: REKOVELLE Sales Forecast, till 2035 (USD Billion)
Figure 23.57 Approved Subcutaneous Biologics Market: Repatha Sales Forecast, till 2035 (USD Billion)
Figure 23.58 Approved Subcutaneous Biologics Market: RITUXAN HYCELA / MabThera SC Sales Forecast, till 2035 (USD Billion)
Figure 23.59 Approved Subcutaneous Biologics Market: RYZODEG 70/30 Sales Forecast, till 2035 (USD Billion)
Figure 23.60 Approved Subcutaneous Biologics Market: Saizen Sales Forecast, till 2035 (USD Billion)
Figure 23.61 Approved Subcutaneous Biologics Market: Saxenda Sales Forecast, till 2035 (USD Billion)
Figure 23.62 Approved Subcutaneous Biologics Market: SIMPONI Sales Forecast, till 2035 (USD Billion)
Figure 23.63 Approved Subcutaneous Biologics Market: Skyrizi Sales Forecast, till 2035 (USD Billion)
Figure 23.64 Approved Subcutaneous Biologics Market: SOLIQUA 100/33 Sales Forecast, till 2035 (USD Billion)
Figure 23.65 Approved Subcutaneous Biologics Market: STELARA Sales Forecast, till 2035 (USD Billion)
Figure 23.66 Approved Subcutaneous Biologics Market: Strensiq Sales Forecast, till 2035 (USD Billion)
Figure 23.67 Approved Subcutaneous Biologics Market: TAKHZYRO Sales Forecast, till 2035 (USD Billion)
Figure 23.68 Approved Subcutaneous Biologics Market: Taltz Sales Forecast, till 2035 (USD Billion)
Figure 23.69 Approved Subcutaneous Biologics Market: Tecentriq Sales Forecast, till 2035 (USD Billion)
Figure 23.70 Approved Subcutaneous Biologics Market: TEGSEDI Sales Forecast, till 2035 (USD Billion)
Figure 23.71 Approved Subcutaneous Biologics Market: TEZSPIRE Sales Forecast, till 2035 (USD Billion)
Figure 23.72 Approved Subcutaneous Biologics Market: Toujeo Sales Forecast, till 2035 (USD Billion)
Figure 23.73 Approved Subcutaneous Biologics Market: TREMFYA Sales Forecast, till 2035 (USD Billion)
Figure 23.74 Approved Subcutaneous Biologics Market: TRESIBA Sales Forecast, till 2035 (USD Billion)
Figure 23.75 Approved Subcutaneous Biologics Market: Trulicity Sales Forecast, till 2035 (USD Billion)
Figure 23.76 Approved Subcutaneous Biologics Market: Tysabri Sales Forecast, till 2035 (USD Billion)
Figure 23.77 Approved Subcutaneous Biologics Market: Ultomiris Sales Forecast, till 2035 (USD Billion)
Figure 23.78 Approved Subcutaneous Biologics Market: Victoza Sales Forecast, till 2035 (USD Billion)
Figure 23.79 Approved Subcutaneous Biologics Market: Voxzogo Sales Forecast, till 2035 (USD Billion)
Figure 23.80 Approved Subcutaneous Biologics Market: VYVGART Hytrulo Sales Forecast, till 2035 (USD Billion)
Figure 23.81 Approved Subcutaneous Biologics Market: WAINUA Sales Forecast, till 2035 (USD Billion)
Figure 23.82 Approved Subcutaneous Biologics Market: Xgeva / RANMARK Sales Forecast, till 2035 (USD Billion)
Figure 23.83 Approved Subcutaneous Biologics Market: XOLAIR Sales Forecast, till 2035 (USD Billion)
Figure 23.84 Approved Subcutaneous Biologics Market: XULTOPHY Sales Forecast, till 2035 (USD Billion)
Figure 23.85 Approved Subcutaneous Biologics Market: ZEPBOUND Sales Forecast, till 2035 (USD Billion)
Figure 24.1 Approved Subcutaneous Biologics Market: Distribution by Leading Drug Developers (based on the forecasted sales of subcutaneous biologics in the current year (USD Billion))
Figure 24.2 Approved Subcutaneous Biologics Market: Distribution by Leading Drug Developers (based on the forecasted sales of subcutaneous biologics in the year 2030 (USD Billion))
Figure 24.3 Approved Subcutaneous Biologics Market: Distribution by Leading Drug Developers (based on the forecasted sales of subcutaneous biologics in the year 2035 (USD Billion))
Figure 25.1 Licensing Agreements: Distribution of Financial Components
Figure 25.2 Licensing Agreements: Illustrative Scenario based Opportunity Estimation
Figure 25.3 Global Subcutaneous Biologics Formulation Technologies Market, till 2035 (USD Million)
Figure 25.4 Global Subcutaneous Biologics Formulation Technologies Market, till 2035: Conservative Scenario (USD Million)
Figure 25.5 Global Subcutaneous Biologics Formulation Technologies Market, till 2035: Optimistic Scenario (USD Million)
Figure 26.1 Subcutaneous Biologics Formulation Technologies Market: Distribution by Fundamental Principle, Current year and 2035
Figure 26.2 Subcutaneous Biologics Formulation Technologies Market for Encapsulation Principle, till 2035 (USD Million)
Figure 26.3 Subcutaneous Biologics Formulation Technologies Market for Complex Formation Principle, till 2035 (USD Million)
Figure 26.4 Subcutaneous Biologics Formulation Technologies Market for Conjugation Principle, till 2035 (USD Million)
Figure 26.5 Subcutaneous Biologics Formulation Technologies Market for Amino-acid Interaction Principle, till 2035 (USD Million)
Figure 26.6 Subcutaneous Biologics Formulation Technologies Market for Other Principles, till 2035 (USD Million)
Figure 27.1 Subcutaneous Biologics Formulation Technologies Market: Distribution by End-user, Current year and 2035
Figure 27.2 Subcutaneous Biologics Formulation Technologies Market for Pharmaceutical and Biopharmaceutical Companies, till 2035 (USD Million)
Figure 27.3 Subcutaneous Biologics Formulation Technologies Market for Biotechnology Companies, till 2035 (USD Million)
Figure 27.4 Subcutaneous Biologics Formulation Technologies Market for MedTech Companies, till 2035 (USD Million)
Figure 27.5 Subcutaneous Biologics Formulation Technologies Market for Educational Institutes, till 2035 (USD Million)
Figure 27.6 Subcutaneous Biologics Formulation Technologies Market for Medical Equipment Manufacturers, till 2035 (USD Million)
Figure 27.7 Subcutaneous Biologics Formulation Technologies Market for Contract Drug Manufacturing Organizations, till 2035 (USD Million)
Figure 27.8 Subcutaneous Biologics Formulation Technologies Market for Other End-users, till 2035 (USD Million)
Figure 28.1 Subcutaneous Biologics Formulation Technologies Market: Distribution by Therapeutic Area, Current year and 2035
Figure 28.2 Subcutaneous Biologics Formulation Technologies Market for Oncological Disorders, till 2035 (USD Million)
Figure 28.3 Subcutaneous Biologics Formulation Technologies Market for Metabolic Disorders, till 2035 (USD Million)
Figure 28.4 Subcutaneous Biologics Formulation Technologies Market for Infectious Diseases, till 2035 (USD Million)
Figure 28.5 Subcutaneous Biologics Formulation Technologies Market for Ocular Disorders, till 2035 (USD Million)
Figure 28.6 Subcutaneous Biologics Formulation Technologies Market for Autoimmune Disorders, till 2035 (USD Million)
Figure 28.7 Subcutaneous Biologics Formulation Technologies Market for Neurological Disorders, till 2035 (USD Million)
Figure 28.8 Subcutaneous Biologics Formulation Technologies Market for Immunological Disorders, till 2035 (USD Million)
Figure 28.9 Subcutaneous Biologics Formulation Technologies Market for Other Disorders, till 2035 (USD Million)
Figure 29.1 Subcutaneous Biologics Formulation Technologies Market: Distribution by Key Geographical Regions, Current year and 2035
Figure 29.2 Subcutaneous Biologics Formulation Technologies Market in North America, till 2035 (USD Million)
Figure 29.3 Subcutaneous Biologics Formulation Technologies Market in Europe, till 2035 (USD Million)
Figure 29.4 Subcutaneous Biologics Formulation Technologies Market in Asia-Pacific, till 2035 (USD Million)
Figure 29.5 Penetration-Growth (P-G) Matrix: Key Geographical Regions
Figure 30.1 Subcutaneous Biologics Formulation Technologies Market: Distribution by Payment Method Employed, Current year and 2035
Figure 30.2 Subcutaneous Biologics Formulation Technologies Market based on Milestone Payments, till 2035 (USD Million)
Figure 30.3 Subcutaneous Biologics Formulation Technologies Market based on Upfront Payments, till 2035 (USD Million)
Figure 32.1 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, till 2035 (USD Million)
Figure 32.2 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, till 2035 (Million Units)
Figure 32.3 Global Large Volume Wearable Injectors Market for Insulin Drugs, till 2035 (USD Million)
Figure 32.4 Global Large Volume Wearable Injectors Market for Insulin Drugs, till 2035 (Million Units)
Figure 32.5 Global Autoinjectors Market, till 2035 (USD Billion)
Figure 32.6 Global Needle-free Injection Systems Market, till 2035 (USD Million)
Figure 32.7 Global Novel Drug Reconstitution Systems Market, till 2035 (USD Billion)
Figure 32.8 Global Prefilled Syringes Market, till 2035 (USD Million)
Figure 33.1 Concluding Remarks: Approved Subcutaneous Biologics Landscape
Figure 33.2 Concluding Remarks: Clinical-stage Subcutaneous Biologics Landscape
Figure 33.3 Concluding Remarks: Technology Landscape
Figure 33.4 Concluding Remarks: Partnerships and Collaborations (Subcutaneous Formulation Technology)
Figure 33.5 Concluding Remarks: Approved Subcutaneous Biologics Market Forecast and Opportunity Analysis
Figure 33.6 Concluding Remarks: Subcutaneous Biologics Formulation Technologies Market Forecast and Opportunity Analysis
 
LIST OF TABLES

Table 6.1 Comparison of Characteristics of Small Molecules and Biologics
Table 6.2 Parenteral Routes of Administration
Table 6.3 Parenteral Drug Formulations: Associated Physical and Chemical Instabilities
Table 6.4 Parenteral Drug Formulations: Key Excipients
Table 7.1 Approved Subcutaneous Biologics: Market Landscape
Table 7.2 Approved Subcutaneous Biologics: Information on Type of Therapy, Route and Method of Administration
Table 7.3 Approved Subcutaneous Biologics: Information on Dosing Frequency and Concentration of Dose
Table 7.4 Approved Subcutaneous Biologics: Information on Target Disease Indication and Therapeutic Area
Table 7.5 Approved Subcutaneous Biologics: Information on Type of Drug Delivery Device
Table 7.6 Approved Subcutaneous Biologics: List of Developers
Table 8.1 List of Top Approved Subcutaneous Biologics
Table 8.2 BENLYSTA (Human Genome Sciences): Phase of Development, Route of Administration, and Target Disease Indication
Table 8.3 BENLYSTA (Human Genome Sciences): Success Protocol Analysis Parameters
Table 8.4 BESREMi (Pharmaessentia): Phase of Development, Route of Administration, and Target Disease Indication
Table 8.5 BESREMi (Pharmaessentia): Success Protocol Analysis Parameters
Table 8.6 COSENTYX (Novartis): Phase of Development, Route of Administration, and Target Disease Indication
Table 8.7 COSENTYX (Novartis): Success Protocol Analysis Parameters
Table 8.8 DARZALEX FASPRO (Halozyme): Phase of Development, Route of Administration, and Target Disease Indication
Table 8.9 DARZALEX FASPRO (Halozyme): Success Protocol Analysis Parameters
Table 8.10 DUPIXENT (Regeneron Pharma): Phase of Development, Route of Administration, and Target Disease Indication
Table 8.11 DUPIXENT (Regeneron Pharma): Success Protocol Analysis Parameters
Table 8.12 Enbrel (Amgen): Phase of Development, Route of Administration, and Target Disease Indication
Table 8.13 Enbrel (Amgen): Success Protocol Analysis Parameters
Table 8.14 HEMLIBRA (Roche): Phase of Development, Route of Administration, and Target Disease Indication
Table 8.15 HEMLIBRA (Roche): Success Protocol Analysis Parameters
Table 8.16 Prolia / Pralia (Amgen): Phase of Development, Route of Administration, and Target Disease Indication
Table 8.17 Prolia / Pralia (Amgen): Success Protocol Analysis Parameters
Table 8.18 STELARA (Janssen Biotech): Phase of Development, Route of Administration, and Target Disease Indication
Table 8.19 STELARA (Janssen Biotech): Success Protocol Analysis Parameters
Table 8.20 Trulicity (Eli Lilly): Phase of Development, Route of Administration, and Target Disease Indication
Table 8.21 Trulicity (Eli Lilly): Success Protocol Analysis Parameters
Table 9.1 Clinical-stage Subcutaneous Biologics: Market Landscape
Table 9.2 Clinical-stage Subcutaneous Biologics: Information on Type of Therapy, Mechanism of Action and Dosing Frequency
Table 9.3 Clinical-stage Subcutaneous Biologics: Information on Drug Designation
Table 9.4 Clinical-stage Subcutaneous Biologics: Information on Target Disease Indication and Therapeutic Area
Table 9.5 Clinical-stage Subcutaneous Biologics: List of Developers
Table 10.1 Subcutaneous Formulation Technologies: Information on Fundamental Principle and Type of Molecule
Table 10.2 Subcutaneous Formulation Technologies: Information on Route of Administration
Table 10.3 Subcutaneous Formulation Technologies: Information on Therapeutic Area
Table 10.4 Subcutaneous Formulation Technologies: Information on Key Characteristics
Table 10.5 Subcutaneous Formulation Technologies: List of Developers
Table 12.1 Subcutaneous Formulation Technologies Developers: List of Companies Profiled
Table 12.2 CD Bioparticles: Company Snapshot
Table 12.3 CD Bioparticles: Technology Portfolio
Table 12.4 Creative Biolabs: Company Snapshot
Table 12.5 Creative Biolabs: Technology Portfolio
Table 12.6 Creative Biolabs: Recent Developments and Future Outlook
Table 12.7 Creative BioMart: Company Snapshot
Table 12.8 Creative BioMart: Technology Portfolio
Table 12.9 Creative BioMart: Recent Developments and Future Outlook
Table 12.10 Pacira BioSciences: Company Snapshot
Table 12.11 Pacira BioSciences: Technology Portfolio
Table 12.12 Pacira BioSciences: Recent Developments and Future Outlook
Table 12.13 The Wyss Institute: Company Snapshot
Table 12.14 The Wyss Institute: Technology Portfolio
Table 12.15 Xeris Biopharma: Company Snapshot
Table 12.16 Xeris Biopharma: Technology Portfolio
Table 12.17 Xeris Biopharma: Recent Developments and Future Outlook
Table 12.18 Adocia: Company Snapshot
Table 12.19 Adocia: Technology Portfolio
Table 12.20 Adocia: Recent Developments and Future Outlook
Table 12.21 Ascendis Pharma: Company Snapshot
Table 12.22 Ascendis Pharma: Technology Portfolio
Table 12.23 Ascendis Pharma: Recent Developments and Future Outlook
Table 12.24 Alteogen: Company Snapshot
Table 12.25 Alteogen: Technology Portfolio
Table 12.26 Alteogen: Recent Developments and Future Outlook
Table 12.27 Foresee Pharmaceuticals: Company Snapshot
Table 12.28 Foresee Pharmaceuticals: Technology Portfolio
Table 12.29 Foresee Pharmaceuticals: Recent Developments and Future Outlook
Table 13.1 Partnerships and Collaborations: Information on Type of Partner, Year of Agreement and Type of Partnership, since 2019
Table 13.2 Partnerships and Collaborations: Information on Therapeutic Area and Type of Agreement (Country-wise and Continent-wise)
Table 14.1 Large Volume Wearable Injectors for Non-Insulin Drugs: Information on Status of Development, Type of Device and Usability
Table 14.2 Large Volume Wearable Injectors for Non-Insulin Drugs: Information on Type of Dose, Type of Drug Container and Mode of Drug Filling
Table 14.3 Large Volume Wearable Injectors for Non-Insulin Drugs: Information on Container Volume (mL), Route of Administration and Mode of Injection
Table 14.4 Large Volume Wearable Injectors for Non-Insulin Drugs: Information on Mechanism of Action / Driving Force and Type of Technology
Table 14.5 Large Volume Wearable Injectors for Non-Insulin Drugs: Information on Availability of Connectivity Feature and Type of Compatible Drug
Table 14.6 Large Volume Wearable Injectors for Non-Insulin Drugs: Information on Compatibility with High Viscosity Drugs and Therapeutic Area
Table 14.7 Large Volume Wearable Injectors for Insulin Drugs: Information on Status of Development, Type of Device and Usability
Table 14.8 Large Volume Wearable Injectors for Insulin Drugs: Information on Type of Dose, Mode of Drug Filling and Container Volume (mL)
Table 14.9 Large Volume Wearable Injectors for Insulin Drugs: Information on Type of Diabetes, Type of Combination Insulin and Period of Use (days)
Table 14.10 Large Volume Wearable Injectors for Insulin Drugs: Information on Type of Device Control Feature and Availability of Interoperable Device
Table 14.11 Large Volume Wearable Injectors for Insulin Drugs: Information on Availability of CGM / BGM system, Availability of Automatic Insulin Delivery / Artificial Pancreases and Type of Automated Insulin Delivery Feature
Table 14.12 Large Volume Wearable Injectors for Insulin Drugs: Information on Availability of Connectivity Feature and Waterproof Capabilities
Table 14.13 Large Volume Drug Device Combinations for Non-Insulin Drugs: Information on Developer, Status of Development, Type of Device and Usability
Table 14.14 Large Volume Drug Device Combinations for Non-Insulin Drugs: Information on Type of Dose, Mode of Drug Filling, Type of Drug Container and Container Volume (mL)
Table 14.15 Large Volume Drug Device Combinations for Non-Insulin Drugs: Information on Route of Administration, Mode of Injection and Type of Compatible Drug
Table 14.16 Large Volume Drug Device Combinations for Non-Insulin Drugs: Information on Type of Technology, Mechanism of Action / Driving Force and Therapeutic Area
Table 14.17 Autoinjectors: Overall Market Landscape
Table 14.18 Autoinjectors: Information on Requirement of Needle, Volume of Container, Type of Dose Delivered and Route of Administration
Table 14.19 Autoinjectors: Information on Type of Actuation Mechanism, Type of Feedback Mechanism, Availability of Connectivity Feature and Target Indication
Table 14.20 Autoinjectors: Information on Type of Molecule Delivered and End-user
Table 14.21 Pen Injectors: Development Landscape
Table 14.22 List of Smart Pen Injectors
Table 14.23 List of Drug and Pen Injector Combination Products
Table 14.24 List of Needle-free Injection Systems
Table 14.25 Needle-free Injection Systems: Information on Type of Actuation Mechanism
Table 14.26 Needle-free Injection Systems: Information on Route of Administration
Table 14.27 Needle-free Injection Systems: Information on Type of Formulation Administered
Table 14.28 Needle-free Injection Systems: Information on Type of Drugs Delivered
Table 14.29 Needle-free Injection Systems: Information on Therapeutic Area
Table 14.30 Needle-free Injection Systems: Information on Usability
Table 14.31 Novel Drug Reconstitution Systems: Information on Manufacturer, Type of Device, Number of Chambers, Physical State of Drug and Certifications / Accreditations
Table 14.32 Novel Drug Reconstitution Systems: Information on Container Fabrication Material, Type of Plastic, Volume, Drug Class, Device Usability and Provisions for Self-Administration
Table 14.33 Novel Drug Reconstitution Systems: Information on Type of Pre-sterilized Device, User-sterilized Device, Sterilization Equipment Used and Type of Technology
Table 14.34 Prefilled Syringes: List of Products
Table 14.35 Prefilled Syringe Combination Products: List of Approved Drugs, 2013-2023
Table 14.36 List of Other Drugs Available in Prefilled Syringe Format
Table 14.37 Implants: Development Landscape
Table 14.38 Implants: Information on Material Type, Treatment Duration and Type of Delivery System
Table 14.39 Implants: Subcutaneous Implants Eluting Small Molecules
Table 17.1 Number of Approved Subcutaneous Drugs since 2018 (not having sales information)
Table 25.1 Subcutaneous Biologics Formulation Technologies: Average Upfront and Milestone Payment, since 2019 (USD Million)
Table 25.2 Licensing Deals: Tranches of Milestone Payments
Table 31.1 Leading Players: Based on Number of Technology Licensing / Utilization Deals
Table 31.2 Leading Players: Based on Number of Partnership Deals
Table 34.1 Rx Bandz: Company Snapshot
Table 34.2 Oval Medical Technologies: Company Snapshot
Table 34.3 Lindy Biosciences: Company Snapshot
Table 34.4 Subcuject: Company Snapshot
Table 34.5 Qlibrium: Company Snapshot
Table 34.6 Intas Pharmaceuticals: Company Snapshot
Table 34.7 Elcam Medical: Company Snapshot
Table 34.8 IDEO: Company Snapshot
Table 34.9 Pharma Consult: Company Snapshot
Table 34.10 Medincell: Company Snapshot
Table 34.11 Xeris Biopharma: Company Snapshot
Table 34.12 IDT Biologika: Company Snapshot
Table 35.1 Approved Subcutaneous Biologics: Distribution by Initial Approval Year
Table 35.2 Approved Subcutaneous Biologics: Distribution by Type of Biologic
Table 35.3 Approved Subcutaneous Biologics: Distribution by Initial Approval Year and Type of Biologic
Table 35.4 Approved Subcutaneous Biologics: Distribution by Type of Therapy
Table 35.5 Approved Subcutaneous Biologics: Distribution by Route of Administration
Table 35.6 Approved Subcutaneous Biologics: Distribution by Method of Administration
Table 35.7 Approved Subcutaneous Biologics: Distribution by Dosing Frequency
Table 35.8 Approved Subcutaneous Biologics: Distribution by Concentration of Dose
Table 35.9 Approved Subcutaneous Biologics: Distribution by Target Disease Indications
Table 35.10 Approved Subcutaneous Biologics: Distribution by Therapeutic Area
Table 35.11 Approved Subcutaneous Biologics: Distribution by Type of Drug Delivery Device
Table 35.12 Approved Subcutaneous Biologic Developers: Distribution by Year of Establishment
Table 35.13 Approved Subcutaneous Biologics Developers: Distribution by Company Size
Table 35.14 Approved Subcutaneous Biologics Developers: Distribution by Location of Headquarters (Region)
Table 35.15 Approved Subcutaneous Biologics Developers: Distribution by Location of Headquarters (Country)
Table 35.16 Approved Subcutaneous Biologics Developers: Distribution by Company Size and Location of Headquarters (Region)
Table 35.17 Most Active Developers: Distribution by Number of Approved Therapies
Table 35.18 Clinical-stage Subcutaneous Biologics: Phase of Development
Table 35.19 Clinical-stage Subcutaneous Biologics: Distribution by Type of Biologic
Table 35.20 Clinical-Stage Subcutaneous Biologics: Distribution by Stage of Development and Type of Biologic
Table 35.21 Clinical-stage Subcutaneous Biologics: Distribution by Type of Therapy
Table 35.22 Clinical-stage Subcutaneous Biologics: Distribution by Mechanism of Action
Table 35.23 Clinical-stage Subcutaneous Biologics: Distribution by Dosing Frequency
Table 35.24 Clinical-stage Subcutaneous Biologics: Distribution by Drug Designation
Table 35.25 Clinical-stage Subcutaneous Biologics: Distribution by Target Disease Indication
Table 35.26 Clinical-stage Subcutaneous Biologics: Distribution by Therapeutics Area
Table 35.27 Clinical-stage Subcutaneous Biologics: Distribution by Stage of Development and Therapeutics Area
Table 35.28 Clinical-stage Subcutaneous Biologics: Distribution by Therapeutic Area and Type of Biologic
Table 35.29 Clinical-stage Subcutaneous Biologic Developers: Distribution by Year of Establishment
Table 35.30 Clinical-stage Subcutaneous Biologics Developers: Distribution by Company Size
Table 35.31 Clinical-stage Subcutaneous Biologics Developers: Distribution by Location of Headquarters (Region)
Table 35.32 Clinical-stage Subcutaneous Biologics Developers: Distribution by Company Size and Location of Headquarters (Region)
Table 35.33 Most Active Developers: Distribution by Number of Clinical-stage Therapies
Table 35.34 Subcutaneous Formulation Technologies: Distribution by Fundamental Principle
Table 35.35 Subcutaneous Formulation Technologies: Distribution by Type of Molecule
Table 35.36 Subcutaneous Formulation Technologies: Distribution by Route of Administration
Table 35.37 Subcutaneous Formulation Technologies: Distribution by Therapeutic Area
Table 35.38 Subcutaneous Formulation Technologies: Distribution by Type of Molecule and Route of Administration
Table 35.39 Subcutaneous Formulation Technologies: Distribution by Key Characteristics
Table 35.40 Subcutaneous Formulation Technology Developers: Distribution by Year of Establishment
Table 35.41 Subcutaneous Formulation Technology Developers: Distribution by Company Size
Table 35.42 Subcutaneous Formulation Technology Developers: Distribution by Location of Headquarters (Region)
Table 35.43 Subcutaneous Formulation Technology Developers: Distribution by Company Size and Location of Headquarters (Region)
Table 35.44 Pacira BioSciences: Annual Revenues, since 2020 (USD Million)
Table 35.45 Xeris Pharmaceuticals: Annual Revenues, since 2020 (USD Million)
Table 35.46 ADOCIA: Annual Revenues, since 2019 (EUR Million)
Table 35.47 Ascendis Pharma: Annual Revenues, since 2020 (EUR Million)
Table 35.48 Foresee Pharmaceuticals: Annual Revenues, since 2020 (NTD Million)
Table 35.49 Partnerships and Collaborations: Cumulative Year-wise Trend, since 2019
Table 35.50 Partnerships and Collaborations: Distribution by Type of Partnership
Table 35.51 Partnerships and Collaborations: Distribution by Year and Type of Partnership, since 2019
Table 35.52 Partnerships and Collaborations: Distribution by Type of Partner
Table 35.53 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 35.54 Partnerships and Collaborations: Distribution by Location of Headquarters of Partner
Table 35.55 Most Active Players: Distribution by Number of Partnerships
Table 35.56 Partnerships and Collaborations: Distribution by Region
Table 35.57 Partnerships and Collaborations: Distribution by Intercontinental and Intracontinental Agreements
Table 35.58 Partnerships and Collaborations: Distribution by International and Local Agreements
Table 35.59 Large Volume Wearable Injectors: Distribution by Type of Device (By Drug Administered)
Table 35.60 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Status of Development
Table 35.61 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Device
Table 35.62 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Usability
Table 35.63 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Dose
Table 35.64 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Drug Container
Table 35.65 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Mode of Drug Filling
Table 35.66 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Container Volume (mL)
Table 35.67 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Route of Administration
Table 35.68 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Mode of Injection
Table 35.69 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Mechanism of Action / Driving Force
Table 35.70 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Technology
Table 35.71 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Availability for Connectivity Feature
Table 35.72 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Compatible Drug
Table 35.73 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Compatibility with High Viscosity Drugs
Table 35.74 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Therapeutic Area
Table 35.75 Most-Active Players: Distribution by Number of Large Volume Wearable Injectors Manufactured for Non-Insulin Drugs
Table 35.76 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Status of Development
Table 35.77 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type of Device
Table 35.78 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Usability
Table 35.79 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type of Dose
Table 35.80 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Mode of Drug Filling
Table 35.81 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Container Volume (mL)
Table 35.82 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type of Diabetes
Table 35.83 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type of Combination Insulin
Table 35.84 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Period of use (Days)
Table 35.85 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type of Device Control Feature
Table 35.86 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Interoperable Device
Table 35.87 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Continuous Glucose Monitoring (CGM) / Blood Glucose Monitoring (BGM) System
Table 35.88 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Automatic Insulin Delivery (AID) / Artificial Pancreas
Table 35.89 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type of Automated Insulin Delivery
Table 35.90 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Connectivity Feature
Table 35.91 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Waterproof Capabilities
Table 35.92 Most-Active Players: Large Volume Wearable Injectors for Insulin Drugs
Table 35.93 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Status of Development
Table 35.94 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Device
Table 35.95 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Usability
Table 35.96 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Dose
Table 35.97 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Drug Container
Table 35.98 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Mode of Drug Filling
Table 35.99 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Container Volume (mL)
Table 35.100 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Route of Administration
Table 35.101 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Mode of Injection
Table 35.102 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Compatible Drug
Table 35.103 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Mechanism of Action / Driving Force
Table 35.104 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Technology
Table 35.105 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Therapeutic Area
Table 35.106 Most-Active Players: Distribution by Number of Drug Device Combinations for Non-Insulin Drugs
Table 35.107 Autoinjectors: Distribution by Stage of Development
Table 35.108 Autoinjectors: Distribution by Usability
Table 35.109 Autoinjectors: Distribution by Type of Primary Drug Container
Table 35.110 Autoinjectors: Distribution by Requirement of Needle
Table 35.111 Autoinjectors: Distribution by Volume of Container
Table 35.112 Autoinjectors: Distribution by Type of Dose Delivered
Table 35.113 Autoinjectors: Distribution by Route of Administration
Table 35.114 Autoinjectors: Distribution by Type of Actuation Mechanism
Table 35.115 Autoinjectors: Distribution by Type of Feedback Mechanism
Table 35.116 Autoinjectors: Distribution by Availability of Connectivity Feature
Table 35.117 Autoinjectors: Distribution by Target Indication
Table 35.118 Autoinjectors: Distribution by Type of Molecule Delivered
Table 35.119 Autoinjectors: Distribution by End User
Table 35.120 Most Active Players: Distribution by Number of Autoinjectors
Table 35.121 Pen Injectors: Distribution by Type of Dose
Table 35.122 Pen Injectors: Distribution by Volume Storage / Capacity
Table 35.123 Pen Injectors: Distribution by Usability
Table 35.124 Most Active Players: Distribution by Number of Pen Injectors
Table 35.125 Needle-free Injection Systems: Distribution by Type of Actuation Mechanism
Table 35.126 Needle-free Injection Systems: Distribution by Route of Administration
Table 35.127 Needle-free Injection Systems: Distribution by Type of Formulation Administered
Table 35.128 Needle-free Injection Systems: Distribution by Type of Drug Delivered
Table 35.129 Needle-free Injection Systems: Distribution by Therapeutic Area
Table 35.130 Needle-free Injection Systems: Distribution by Usability
Table 35.131 Needle-free Injection Systems: Distribution by Type of Formulation Administered and Actuation Mechanism
Table 35.132 Novel Drug Reconstitution Systems: Distribution by Type of Device
Table 35.133 Novel Drug Reconstitution Systems: Distribution by Type of Chamber
Table 35.134 Novel Drug Reconstitution Systems: Distribution by Type of Device and Type of Chamber
Table 35.135 Novel Drug Reconstitution Systems: Distribution by Physical State of Drug
Table 35.136 Novel Drug Reconstitution Systems: Distribution by Container Fabrication Material
Table 35.137 Novel Drug Reconstitution Systems: Distribution by Volume of Container (mL)
Table 35.138 Novel Drug Reconstitution Systems: Distribution by Drug Class
Table 35.139 Novel Drug Reconstitution Systems: Distribution by Device Usability
Table 35.140 Novel Drug Reconstitution Systems: Distribution by Container Fabrication Material and Device Usability
Table 35.141 Novel Drug Reconstitution Systems: Distribution by Type of Pre-sterilized Devices
Table 35.142 Novel Drug Reconstitution Systems: Distribution by Type of User-sterilized Devices
Table 35.143 Novel Drug Reconstitution Systems: Distribution by Type of Sterilization Equipment Used
Table 35.144 Most-Active Players: Distribution by Number of Novel Drug Reconstitution Systems Manufactured
Table 35.145 Prefilled Syringes: Distribution by Type of Barrel Fabrication Material
Table 35.146 Prefilled Syringes: Distribution by Number of Barrel Chambers
Table 35.147 Prefilled Syringes: Distribution by Type of Needle System
Table 35.148 Prefilled Syringes: Distribution by Volume of Syringe
Table 35.149 Most Active Players: Distribution by Number of Prefilled Syringes
Table 35.150 Implants: Distribution by Phase of Development
Table 35.151 Implants: Distribution by Therapeutic Area
Table 35.152 Implants: Distribution by Implant Material
Table 35.153 Implants: Distribution by Treatment Duration
Table 35.154 Implants: Distribution by Type of Delivery System
Table 35.155 Most Active Players: Distribution By Number of Implants
Table 35.156 Global Approved Subcutaneous Biologics Market, till 2035: Base Scenario (USD Billion)
Table 35.157 Global Approved Subcutaneous Biologics Market, till 2035: Conservative Scenario (USD Billion)
Table 35.158 Global Approved Subcutaneous Biologics Market, till 2035: Optimistic Scenario (USD Billion)
Table 35.159 Approved Subcutaneous Biologics Market: Distribution by Type of Biologic, Current year and 2035
Table 35.160 Approved Subcutaneous Biologics Market for Antibodies, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.161 Approved Subcutaneous Biologics Market for Proteins, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.162 Approved Subcutaneous Biologics Market for Nucleotides, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.163 Approved Subcutaneous Biologics Market: Distribution by Type of Therapy, Current year and 2035
Table 35.164 Approved Subcutaneous Biologics Market for Monotherapy, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.165 Approved Subcutaneous Biologics Market for Combination Therapy, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.166 Approved Subcutaneous Biologics Market for Both Monotherapy and Combination Therapy, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.167 Approved Subcutaneous Biologics Market: Distribution by Method of Administration, Current year and 2035
Table 35.168 Approved Subcutaneous Biologics Market for Administration via Injection, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.169 Approved Subcutaneous Biologics Market for Administration via Infusion till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.170 Approved Subcutaneous Biologics Market for both Injection and Infusion, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.171 Approved Subcutaneous Biologics Market: Distribution by Therapeutic Area, Current year and 2035
Table 35.172 Approved Subcutaneous Biologics Market for Autoimmune Disorders, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.173 Approved Subcutaneous Biologics Market for Metabolic Disorders, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.174 Approved Subcutaneous Biologics Market for Oncological Disorders, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.175 Approved Subcutaneous Biologics Market for Hematological Disorders, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.176 Approved Subcutaneous Biologics Market for Inflammatory Disorders, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.177 Approved Subcutaneous Biologics Market for Neurological Disorders, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.178 Approved Subcutaneous Biologics Market for Bone Disorders, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.179 Approved Subcutaneous Biologics Market for Other Disorders, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.180 Approved Subcutaneous Biologics Market: Distribution by Geographical Regions, Current year and 2035
Table 35.181 Approved Subcutaneous Biologics Market in North America, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.182 Approved Subcutaneous Biologics Market in Europe, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.183 Approved Subcutaneous Biologics Market in Asia-Pacific, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.184 Approved Subcutaneous Biologics Market in Middle East and North Africa, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.185 Approved Subcutaneous Biologics Market in Latin America, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.186 Actemra / RoActemra Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.187 Acthar Gel / ACTHar Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.188 AIMOVIG Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.189 AJOVY Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.190 AMVUTTRA Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.191 ARANESP / NESP Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.192 Basaglar / Abasaglar Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.193 BENLYSTA Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.194 Betaseron / Betaferon / EXTAVIA Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.195 CABLIVI Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.196 CIMZIA Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.197 COSENTYX Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.198 CRYSVITA Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.199 DARZALEX FASPRO / DARZALEX SC Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.200 DUPIXENT Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.201 EMGALITY Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.202 Enbrel Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.203 ENSPRYNG Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.204 ENTYVIO Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.205 Epogen / Procrit / Eprex Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.206 EVENITY Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.207 FASENRA Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.208 FIASP Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.209 Forteo / Forsteo Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.210 GATTEX / Revestive Sales Forecast till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.211 Genotropin Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.212 GIVLAARI Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.213 G-LASTA / Peglasta / Neulasta / GRAN Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.214 Gonal-F Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.215 HAEGARDA Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.216 HEMLIBRA Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.217 Herceptin SC / HERCEPTIN HYLECTA Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.218 Hizentra Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.219 Humalog Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.220 HUMIRA Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.221 Humulin Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.222 ILARIS Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.223 Kesimpta Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.224 KEVZARA Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.225 KINERET Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.226 LANTUS Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.227 LEQVIO Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.228 Mircera Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.229 MOUNJARO Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.230 NPLATE Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.231 Nucala Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.232 ORENCIA Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.233 OXLUMO Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.234 PALYNZIQ Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.235 Phesgo Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.236 PLEGRIDY Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.237 PRALUENT Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.238 Prolia / Pralia Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.239 Rebif Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.240 REBLOZYL Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.241 REKOVELLE Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.242 Repatha Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.243 RITUXAN HYCELA / MabThera SC Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.244 RYZODEG 70/30 Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.245 Saizen Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.246 Saxenda Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.247 SIMPONI Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.248 Skyrizi Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.249 SOLIQUA 100/33 Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.250 STELARA Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.251 Strensiq Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.252 TAKHZYRO Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.253 Taltz Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.254 Tecentriq Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.255 TEGSEDI Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.256 TEZSPIRE Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.257 Toujeo Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.258 TREMFYA Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.259 TRESIBA Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.260 Trulicity Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.261 Tysabri Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.262 Ultomiris Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.263 Victoza Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.264 Voxzogo Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.265 VYVGART Hytrulo Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.266 WAINUA Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.267 Xgeva / RANMARK Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.268 XOLAIR Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.269 XULTOPHY Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.270 ZEPBOUND Sales Forecast, till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.271 Approved Subcutaneous Biologics Market: Distribution by Leading Drug Developers (based on sales of subcutaneous biologics in the current year (USD Billion))
Table 35.272 Approved Subcutaneous Biologics Market: Distribution by Leading Drug Developers (based on the forecasted sales of subcutaneous biologics in the year 2030 (USD Billion))
Table 35.273 Approved Subcutaneous Biologics Market: Distribution by Leading Drug Developers (based on the forecasted sales of subcutaneous biologics in the year 2035 (USD Billion))
Table 35.274 Global Subcutaneous Biologics Formulation Technologies Market, till 2035: Base Scenario (USD Million)
Table 35.275 Global Subcutaneous Biologics Formulation Technologies Market, till 2035: Conservative Scenario (USD Million)
Table 35.276 Global Subcutaneous Biologics Formulation Technologies Market, till 2035: Optimistic Scenario (USD Million)
Table 35.277 Global Subcutaneous Formulation Technologies Market: Distribution by Fundamental Principle, Current year and 2035
Table 35.278 Subcutaneous Formulation Technologies Market for Encapsulation Principle, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.279 Subcutaneous Formulation Technologies Market for Complex Formation Principle, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.280 Subcutaneous Formulation Technologies Market for Conjugation Principle, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.281 Subcutaneous Formulation Technologies Market for Amino-Acid Interaction Principle, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.282 Subcutaneous Formulation Technologies Market for Other Principles, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.283 Global Subcutaneous Formulation Technologies Market: Distribution by End User, Current year and 2035
Table 35.284 Subcutaneous Formulation Technologies Market for Pharmaceutical and Biopharmaceutical Companies, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.285 Subcutaneous Formulation Technologies Market for Biotechnology Companies, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.286 Subcutaneous Formulation Technologies Market for MedTech Companies, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.287 Subcutaneous Formulation Technologies Market for Educational Institutes, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.288 Subcutaneous Formulation Technologies Market for Medical Equipment Manufacturers, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.289 Subcutaneous Formulation Technologies Market for Contract Drug Manufacturing Organizations, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.290 Subcutaneous Formulation Technologies Market for Other End Users, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.291 Global Subcutaneous Formulation Technologies Market: Distribution by Therapeutic Area, Current year and 2035
Table 35.292 Subcutaneous Formulation Technologies Market for Oncological Disorders, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.293 Subcutaneous Formulation Technologies Market for Metabolic Disorders, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.294 Subcutaneous Formulation Technologies Market for Infectious Diseases, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.295 Subcutaneous Formulation Technologies Market for Ocular Disorders, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.296 Subcutaneous Formulation Technologies Market for Autoimmune Disorders, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.297 Subcutaneous Formulation Technologies Market for Neurological Disorders, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.298 Subcutaneous Formulation Technologies Market for Immunological Disorders, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.299 Subcutaneous Formulation Technologies Market for Other Disorders, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.300 Global Subcutaneous Formulation Technologies Market: Distribution by Key Geographical Regions, Current year and 2035
Table 35.301 Subcutaneous Formulation Technologies Market in North America, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.302 Subcutaneous Formulation Technologies Market in Europe, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.303 Subcutaneous Formulation Technologies Market in Asia-Pacific, till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 35.304 Global Subcutaneous Formulation Technologies Market: Distribution by Payment Method Employed, Current year and 2035
Table 35.305 Subcutaneous Formulation Technologies Market based on Milestone Payments, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.306 Subcutaneous Formulation Technologies Market based on Upfront Payments, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.307 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, till 2035: Base Scenario (USD Million) (By Value)
Table 35.308 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, till 2035: Base Scenario (USD Million) (By Volume)
Table 35.309 Global Large Volume Wearable Injectors Market for Insulin Drugs, till 2035: Base Scenario (USD Million) (By Value)
Table 35.310 Global Large Volume Wearable Injectors Market for Insulin Drugs, till 2035: Base Scenario (USD Million) (By Volume)
Table 35.311 Global Autoinjectors Market, till 2035: Base Scenario (USD Billion)
Table 35.312 Global Needle-free Injection Systems Market, till 2035: Base Scenario (USD Million)
Table 35.313 Global Novel Drug Reconstitution Systems Market, till 2035: Base Scenario (USD Million)
Table 35.314 Global Prefilled Syringes Market, till 2035: Base Scenario (USD Million)

• Adocia
• Alteogen
• Ascendis Pharma
• CD Bioparticles
• Creative Biolabs
• Creative BioMart
• Foresee Pharmaceuticals
• Pacira Biosciences
• The Wyss Institute 
• Xeris Biopharma

Methodology